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1.1. Breathing during sleep in normal persons 
During wakefulness breathing is mainly controlled by the medullary respiratory centers, 
meeting the metabolic and homeostatic needs of the body, and by the behavioural 
cortical system. Breathing is modulated by chemoreceptors, proprioceptors, mechanical 
lung-, chest wall- and upper airway receptors (fig 1.1)(1). 
During sleep, changes in the control of breathing occur. Sleep is usually divided 
into two main states with its own physiological characteristics: the non-rapid-eye-
movement (NREM) and the rapid-eye-movement (REM) state. The NREM state can be 
subdivided into four stages; the light stages 1 and 2, and the deep stages 3 and 4. In 
the REM state a tonic and phasic type can be distinguished. During sleep basic 
metabolic rate decreases. The activity of the upper airway muscles diminishes during 
sleep. The hypercapnic and hypoxic ventilatory responses decrease after falling 
asleep. This all results in diminished alveolar ventilation with concomitant changes in 
blood gas values. During the REM sleep state rib cage movement decreases, which is 
compensated by an increase in abdominal movements (table 1.1)(2-16). 
Table 1.1 Characteristics of the NREM and REM sleepstages 
Sleepstages NREM U 2 NREMj^ REM REM 
tonic phasic 
Regulation metabolic metabolic behavioural and behavioural 
control control metabolic control control 
Breathing periodic regular mostly regular irregular 
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Figure 1.1 Block diagram of the ventilatory control system, bid: blood; CSF: cerebro spinal fluid; 
centr chemo: central chemoreceptors; perif chemo: peripheral chemoreceptors; 
centres: "respiratory centres' in pons and brainstem; RM motoneur: spinal motor 
neurones of the inspiratory muscles; 1С: intercostal inspiratory muscles; Dia: dia­
phragm; Ppleura: pleural pressure; Elast: elastic properties of the lung parenchyma; 
Patv: alveolar pressure; Raw: airway resistance; VDan: anatomical deadspace; 
VDphys: physiological deadspace; hypothal: hypothalamus; som+visc aff: somatic 
and visceral afférents; cortex: forebrain cortex; Ve: total ventilation; VA: alveolar 
ventilation Pa02: arterial oxygen tension; РаСО
г
: arterial carbon dioxide tension; pHa: 
arterial pH. 
1.2. Disordered breathing during sleep 
1.2.1. Definitions (17-21) 
Disordered breathing during sleep can be divided in apnoea and hypopnoea. Apnoea 
is defined as a cessation of oro-nasal airflow, lasting for at least 10 seconds. 
Hypopnoea is defined as a reduction in ventilation, and a concomitant rise in PC02, 
that lasts for at least 10 seconds. Breathing disorders during sleep can further be 
subdivided into an obstructive, a central and a mixed type, depending on the degree 
of central respiratory efforts. The obstructive type is characterized by diminished 
(hypopnoea) or no (apnoea) oro-nasal airflow, in combination with the presence of 
normal central respiratory effort. The central type is marked by diminished (hypopnoea) 
or no (apnoea) airflow at the nose and mouth, simultaneously accompanied by a 
diminished or absent central respiratoiy effort respectively. In the mixed type a central 
breathing disorder is immediately succeeded by an obstructive one. Usually it starts as 
a central apnoea/ hypopnoea, changing into an obstructive one. When more than 10 
apnoeas and/or hypopnoeas per sleeping hour occur, this is defined as the sleep 
apnoea/hypopnoea syndrome. 
Examples of recordings with obstructive and central apnoea and hypopnoea are 
shown in figure 1.2 and 1.3. 
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Figure 1.2 This nocturnal recording shows oxygen desaturations associated with cessation of 
oro-nasal airflow and the presence of normal or increased respiratory efforts which 
indicates obstructive apnoeas. Furthermore it shows oscillations of the heart rate and 
indications for arousals in the EOG signal. 
Figure 1.3 This nocturnal recording shows oxygen desaturations associated with diminished or 
absent oro-nasal airflow and diminished or absent respiratory efforts which indicates 
central apnoeas/hypopnoeas. Furthermore it shows oscillations of the heart rate and 
indications for rapid eye movements in the EOG signal. 
1.2.2. Polysomnography 
Disordered breathing can be detected by means of Polysomnographie recording. This 
may include the measurement of respiratory oro-nasal airflow, thoracoabdominal 
movement, arterial oxygen saturation, heart rate, carbon dioxide tension, sleep and 
sleep stages (22). Oro-nasal airflow is usually recorded with thermistors. Thoracoabdo-
minal movements are measured by inductive plethysmography. A pulse oximeter is 
used to indicate heart rate and arterial oxygen saturation. Carbon dioxide tension can 
be measured transcutaneously or end-tidal. Sleep stages are defined by EEG, EMG 
and EOG according to the guidelines of Rechtschaffen and Kales (23). Gross body 
movements detected with a wrist actigraph or video recording can indicate presence 
or absence of sleep (24, 25). 
Apnoeas can easily be detected with oro-nasal airflow and thoracoabdominal 
movement. Yet, hypoventilation/hypopnoea can be missed since thermistors and 
inductive plethysmography allow only a qualitative or semi-quantitative indication of 
respiration (22). 
Polysomnographies are usually performed twice in each subject because there 
appears to be a variability in EEG parameters between the first and the second night 
(26). Therefore, the first night is often only used as an acclimatisation night, to 
familiarize the subjects with the equipment and the surroundings. Yet, not much is 
known about the impact of the night-to-night EEG variability on the nocturnal oxygen 
saturation and breathing pattern in patients with chronic obstructive pulmonary disease 
(27, 28). 
1.3. Breathing during sleep in patients with COPD 
1.3.1. Hypoventilation 
Chronic obstructive pulmonary disease (COPD) is a disorder characterized by abnor-
mal tests of expiratory flow that do not change markedly over periods of several 
months (29). 
In patients with COPD, the same physiological changes in breathing during sleep 
occur as in healthy people. Yet, the consequences may be worse because of the 
additional pulmonary characteristics of COPD patients. During the REM state in healthy 
subjects, the activity of the intercostal muscles diminishes, which is compensated for 
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by an increased activity of the diaphragm (table 1.1). In hyperinflated COPD patients 
though, the flattened diaphragm is not able to compensate (30, 31). Moreover, the 
activity of the accessory muscles is reduced during REM (32). Therefore, in patients 
with COPD, ventilation during the REM state is substantially decreased as compared 
to healthy subjects (31). In addition, the shalllow breathing during REM may have more 
effect on alveolar ventilation in COPD patients with a high physiological dead space. 
Moreover, patients with a severe COPD may be less able to hyperventilate after a 
period of hypoventilation, resulting in blood gas values being less restored. 
The diminished ventilation during NREM sleep in healthy subjects is partly due to 
decreased hypercapnic and hypoxic ventilatory responses. COPD patients may have 
blunted chemical responses while awake. Both effects together may lead to severer, 
and prolonged hypoventilation in these patients (33-35). 
1.3.2. Obstructive sleep apnoea/hypopnoea syndrome 
The prevalence of the obstructive sleep apnoea/hypopnoea syndrome is about 1 to 
10% in a general population (37-40). Thus, 1 to 10% of the COPD patients can be 
expected to have a sleep apnoea/hypopnoea syndrome as well. Patients with COPD 
may have characteristics such as advanced age and obesity that predispose to the 
development of a sleep apnoea syndrome (17, 41, 42). 
Confusion about the prevalence of obstructive sleep apnoea in COPD patients was 
caused by a study of Guilleminault et al (43). Ninety-two per cent of the disordered 
breathing during sleep in their COPD patients appeared to be obstructive apnoeas. 
These results were influenced by the selection of their patients; they were all selected 
from a sleep disorder clinic and the mild COPD was a mere coincidence. Many other 
research workers who selected COPD patients randomly from a chest clinic could not 
confirm Guilleminault's results. On the contrary, they demonstrated a prevalence of the 
sleep apnoea syndrome of only 0 to 13% (28, 44-56). Therefore, in general it is 
concluded that the sleep apnoea/hypopnoea syndrome and COPD do not coincide 
more than would be expected for figures of prevalence in a general population. 
Yet, if the combination occurs it results in more profound nocturnal hypoxaemia with 
concomitant consequences. Pulmonary hypertension, right heart failure and secondary 
polycythaemia may develop sooner, which may worsen the prognosis (57-60). Long-
lasting and frequent deviations from normal blood gas values may finally lead to a 
change of the chemical control of breathing (61, 62). 
Oxygen therapy in COPD patients with a sleep apnoea/hypopnoea syndrome may 
lead to a substantial rise in PaC02 and acidosis due to prolonged apnoeas (43, 63, 
64). Apnoeas are normally ended by an arousal and the stimulus to arouse is probably 
the low SaOg. With oxygen suppletion this hypoxaemic stimulus is removed. 
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1.3.3. Oxygen desaturations 
1.3.3.1. Mechanism 
Ventilation in in healthy subjects and in COPD patients decreases after falling asleep. 
This causes a slight drop in Sa02 (28,30, 46,65). Moreover, in COPD patients, during 
the REM state the ventilation may diminish substantially, which results in profound 
oxygen desaturations (28, 30, 31, 44-56, 65-67). 
The magnitude of the oxygen desaturation during REM as well as during the NREM 
state, is modified by the initial baseline saturation. In COPO patients with an initial 
PaO^SaOj relationship lying on the shoulder or on the steep part of the oxygen 
hemoglobin dissociation curve, a decrease in alveolar ventilation will cause a substan-
tial fall in Sa02. In COPD patients who start at the upper horizontal part of the curve, 
the same decrease in alveolar ventilation results in a small drop in Sa02. 
Several studies have postulated that the major cause for the REM hypoxaemia in 
COPD patients is a change in ventilation/perfusion ratio instead of hypoventilation (44, 
51, 68-70). It is unlikely that the results of these studies are relevant, since they are 
derived by analysis that is only reliable in a steady-state of gas transfer, which is not 
the case during REM sleep (31). Of course hypoventilation during REM is associated 
with changes in the ventilation/perfusion ratio but hypoventilation itself is most probably 
the major cause of desaturations. 
Finally, coughing has been suggested as an explanation for the desaturations 
during sleep. Since research has shown that nocturnal coughing occurs predominantly 
during wakefulness, this explanation can be ruled out (71). 
1.3.3.2. Prevalence 
All studies on the prevalence of nocturnal hypoxaemia, since the first one in 1962 have 
shown that nocturnal oxygen desaturations are common in patients with COPD (28, 
44-56, 65-70, 72). Yet, the results of the different studies show a discrepancy in 
prevalence, amplitude and duration of the desaturating episodes (table 1.2). The 
prevalence of nocturnal hypoxaemia ranges from 67 to 100% of the investigated COPD 
patients. The severity of the desaturation is expressed as the maximal drop in the 
oxygen saturation from a baseline level. The mean maximal drop varies from 11 % to 
35%. The duration of the hypoxaemic episodes during steep ranges from 1 to 129 
minutes. 
The episodes of nocturnal desaturations occur predominantly and more profoundly 
during the REM sleep stage (43-56, 65, 66), though several investigators also found 
desaturations during the NREM sleep stage (43, 45, 47-49, 66). 
The reported results are difficult to compare and thus to interpret, because the 
relevant studies differ in methodology. The patient groups studied had different awake 
pulmonary fuction and blood gas values (table 1.2). Sometimes obese patients were 
excluded and sometimes they were not (65). The definitions used for "desaturation" 
and "baseline saturation", on which the results are based, differed. "Desaturation" is 
defined as a decrease in the Sa02 of at least 4 (47, 54, 65), 5 (48, 66) or 10 per cent 
(44, 49, 50) from the baseline saturation. Some investigators define the baseline Sa02 
as the mean value of the Sa0215 to 60 minutes before sleeping, lying in a horizontal 
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Table 1.2 A comparison of study results (First author (ref. nr.)) 
Stradling JR (28) 
Guilleminault С (43) 
Douglas NJ (44) 
Wynne JW (45) 
Fleetham JA (46) 
Uttner MR (47) 
Arand DL (48) 
Catterai! JR (49) 
DeMarco FJ (65) 
Tatsumi К (66) 
Number 
of 
patients 
41 
26 
12 
7 
41 
9 
10 
20 
10 
24 
Daytime 
Pa0 2 
(kPa) 
7.8 
8.9 
6.5 
8.4 
6.9 
8.7 
8.9 
7.2 
9 
9.3 
Daytime 
PaC02 
(kPa) 
6.4 
5.5 
7 
5.4 
6 
5.6 
5.4 
6.2 
5.6 
5.9 
FEV, 
(% pred. or) 
liters) 
0.81 
2.3 I 
-
0.7 I 
26% 
36% 
38% 
0.71 
0.9 I 
_ 
FEV,/ 
FVC 
(%) 
37 
65 
37 
38 
-
42 
-
40 
-
50 
Prevalence of 
desatu rations 
(% of studied 
patients) 
98 
100 
83 
89 
100 
67 
70 
76 
100 
100 
Maximal 
drop in 
Sa0 2 
(%) 
-
-
35 
17 
17 
22 
21 
16 
15 
11 
Duration of 
desatu rations 
(min) 
20-40 
-
2-100 
4-30 
-
1-35 
1-7 
2-129 
-
_ 
position (50, 53, 67) or sometimes a combination of awake Sa02 values in the sitting 
and in the supine position is used (28). Others measured the mean Sa02 in the first 
half hour immediately after falling asleep (44, 45, 49). 
1.3.3.3. Predictability 
Several investigators have tried to find daytime parameters that are able to predict the 
presence and the severity of the nocturnal hypoxaemia in patients with COPD. A 
significarli correlation between the daytime Sa02 or Pa02, and the mean nocturnal 
Sa02, the lowest nocturnal Sa02 and the fall in the Sa02 has been demonstrated (28, 
49, 53, 56, 73). Correlation coefficients vary from 0.67 to 0.87. Also the daytime PaC02 
has appeared to show a significant negative correlation to nocturnal oxygenation with 
correlation roefficients that range from -0.33 to -0.73 (50, 53, 54, 67, 73). Finally, also 
the hypercrpnic and hypoxic ventilatory responses are significantly related to the 
nocturnal Sa02 (46, 47, 50, 66, 67). Nevertheless, even the best prediction equations 
that have been suggested, had wide 95% confidence limits. So no daytime parameter 
can predict the nocturnal Sa02 precisely enough to make sleep studies redundant for 
the individual patient (31, 72). 
1.3.3.4. Consequences 
COPD patients with hypoxaemia during the day have extra nocturnal hypoxaemia (28, 
44-56, 65-70, 72). In patients with daytime normoxaemia, nocturnal oxygen desatura-
tions may occur as well (74, 75). Nocturnal hypoxaemia is associated with an increase 
of the pulmonary artery pressure (31, 76-82). Pulmonary hypertension leads to the 
development of right ventricular failure (83). Furthermore, hypoxaemia induces an 
activation of the erythropoiesis which results in secondary polycythemia (84-87). Also, 
nocturnal hypoxaemia has adverse effects on the myocardial function similar to those 
seen during maximal exercise (88, 89). Arrhythmias may occur during hypoxaemia, 
such as bradycardia, tachycardia, premature ventricular beats and second-degree atrial 
ventricular block (90, 91). 
The mentioned consequences of nocturnal hypoxaemia may finally result in a 
higher mortality rate in patients with COPD. Indeed it has been shown that in patients 
with COPD death occurs more often during the night than in age-matched controls 
(92). 
A variety of studies show that COPD patients have a poor subjective and objective 
quality of sleep (54, 64, 93-95). Yet, results about the correlation between nocturnal 
hypoxaemia and arousals are not consistent. 
Patients with COPD have a low neuropsychological performance as compared to 
healthy controls (96, 97). This impaired neuropsychological function appears to be 
inversely related with the arterial oxygen tension (96, 97). 
Hence it is concluded that hypoxaemia ultimately leads to arterial pulmonary 
hypertension, right heart failure, secondary polycythemia, cardiac arrhythmias. There-
fore survival may be diminished. Furthermore, hypoxaemia may lead to an impaired 
sleep quality and an impaired neuropsychological function which decreases the quality 
of life. 
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1.3.3.5. Therapy 
Oxygen supptetkm 
Since it has been indicated that hypoxaemia in patients with COPD may lead to 
several severe consequences such as pulmonary hypertension and arrhythmias, it 
seems relevant to treat hypoxaemia (76-97). Indeed it has been shown that improve-
ment of hypoxaemia in COPD patients by oxygen supptetion may partly reverse the 
pulmonary hypertension, attenuate secondary polycythaemia, diminish cardiac 
arrhythmias and increase survival (74, 79, 91, 98-101). Oxygen supptetion may also 
have a positive effect on the neuropsychological function and on sleep quality, though 
the research results are not consistent (64, 93, 95, 102-104). 
Progesterone 
Medroxyprogesterone and Chlormadinone acetate are respiratory stimulants that raise 
arterial oxygen tension and reduce carbon dioxide tension in COPD patients during 
wakefulness by centrally stimulating effects (105-108). The results on gas exchange 
during sleep are inconsistent (105-108). 
Acetazolamide 
Acetazolamide is another respiratory stimulant. It induces metabolic acidosis by 
inhibiting carbonic anhydrase. Acetazolamide probably acts at both the peripheral and 
the central chemoreceptors. Not much is known about its effect in patients with COPD. 
Improved blood gas values during the day and at night have been demonstrated in a 
small group of COPD patients (105). 
Almitrine bismesylate 
Almitrine improves daytime and nighttime bloodgas tensions in patients with COPD, 
probably by stimulating the peripheral chemoreceptors (109-111). There are also 
inidications that almitrine may cause a rise in pulmonary artery pressure (112). Since 
the benefits and side effects of almitrine are not definitely defined, its use should be 
monitored carefully. (Almitrine is not available in The Netherlands). 
Protriptyline 
Protriptyline is a tricyclic antidepressant which reduces the amount of time spent in the 
REM sleep state. Some studies have shown an improvement of bloodgas values in 
patients with COPD during the day and the night (113, 114). Anticholinergic side 
effects are common and limit the usefulness of this treatment (113,114). (Protriptyline 
is not available in The Netherlands). 
19 
1.4. Relevant conclusions and consequent aims of the 
current study 
Patients with chronic obstructive pulmonary disease may develop oxygen desaturations 
during sleep. The quantitative descriptions on prevalence and severity in earlier 
research differed substantially. Also, the correlation of the nocturnal oxygen saturation 
and daytime characteristics varied. Therefore the main aim of the first study, which is 
described in chapter 2, was to examine the prevalence of the nocturnal desaturations 
and their relation with daytime parameters in a large group of well-defined patients with 
COPD. 
Sleep studies are often performed twice in each subject because of the first-night 
effect in EEG variables. Not much is known about the influence of this night-to-night 
variability on the nocturnal oxygenation and breathing pattern in patients with COPD. 
In chapter 3 a study is described that examined the oxygen saturation and breathing 
pattern during sleep on two consecutive and two non-consecutive nights in COPD 
patients. 
COPD patients with daytime normoxia or mild hypoxia may develop nocturnal 
oxygen desaturations. Because of their - relatively - normal awake blood gas values, 
these patients will not attract the attention of physicians. Nevertheless, nocturnal 
transient hypoxaemia may be clinically relevant since it adversely affects the pulmon-
ary artery tension. Therefore the prediction of the nocturnal oxygenation from daytime 
patient characteristics is studied in patients with COPD with a daytime Pa02 above 8.0 
kPa (Chapter 4). 
Hypoventilation/hypopnoea is usually determined with thermistors that record the 
oro-nasal airflow and with inductive plethysmography which indicates breathing efforts. 
Since these signals are only qualitative or semi-quantitative, hypoventilation/hypo-
pnoeas can easily be missed. Hypoventilation is defined by an increased arterial PC02. 
Changes in end-tidal PC02 are a reflection of changes in arterial PC02. Therefore the 
usefulness of continuous nocturnal end-tidal PC02 recording to detect hypoventilation/ 
hypopnoea has been studied in patients with COPD and in patients who were sus-
pected to have a sleep apnoea syndrome. This study is reported in chapter 5. 
In a pulmonary clinic it is not always feasible to perform a full conventional sleep 
recording. Movement detectors, such as wrist act ¡graphs, have been shown to define 
sleep times quite accurately. The value of a video movement system to indicate sleep 
times is evaluated and described in chapter 6. 
There are some indications that patients with COPD have a low cognitive function, 
which may be related to daytime hypoxaemia. In this study, the selective attention, as 
a parameter of cognitive function, of patients with COPD is compared to that of 
normals. In addition, the relation of the attention with day- and nighttime characteristics 
is determined as well as the effect of therapeutbal intervention with oxygen suppletion, 
Chlormadinone acetate and acetazolamide (Chapter 7). 
Hypoxaemia has adverse effects on pulmonary artery pressure, cardiac function 
and survival. Therefore it is relevant to treat hypoxaemia. The therapeutic effects of 
oxygen suppletion, and the ventilatory stimulants Chlormadinone acetate and acetazola-
mide, on awake and asleep gas exchange in COPD patients are studied in a placebo 
controlled randomised study. The results are described in chapter 8. 
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2.1. Abstract 
Sixty patients with a chronic obstructive pulmonary disease (COPD) and with FEV, 
values below 65% of predicted were investigated during sleep in order to obtain 
information about the nocturnal oxygenation and its correlation with daytime character­
istics. In addition, the association with breathing disorders was examined. Seventy-
eight percent of the patients developed nocturnal desaturations. At a group level, 
daytime Sa02, Pa02, PaC02, and hypercapnic ventilatory response correlated with the 
nocturnal Sa02. None of these correlations was strong enough to be clinically useful 
for the prediction of the nocturnal oxygen saturation in the individual patient. Most 
episodes with desaturations were associated with central hypoventilation, predominant­
ly during the REM sleep stage. 
2.2. Introduction 
Patients with COPD may develop oxygen desaturations during sleep. These nocturnal 
hypoxaemic episodes are often associated with hypopnoea and/or apnoea (1-5). 
Studies report a wide range of prevalence values (67%-100%) and associated breath­
ing disorders (range 71%-100%). The various results are difficult to interpret and to 
compare because of the differences in used methods and the investigated patient 
populations. Moreover, the patient groups are often small. The purpose of this study is 
to investigate the prevalence of nocturnal desaturations and associated disordered 
breathing, in a large, well defined group of COPD patients. 
2.3. Patients and methods 
Sixty COPD patients, defined according to the American Thoracic Society, with FEV, 
values less than 65% of the predicted value, participated in this study. Their character­
istics are shown in Table 2.1. All patients were in a stable clinical state and were 
allowed their usual medication except benzodiazepines. None of the patients was 
above 125% of their ideal weight. Each subject gave informed consent. The study was 
approved by the Hospital Ethics Committee. 
All subjects were monitored during their sleep. The oxygen saturation, chest wall 
movements, nasal oral airflows, electromyogram of the intercostal muscles and EOG 
were recorded. During the day arterial blood gas samples were taken and several 
pulmonary function parameters were measured. The ventilatory response to carbon 
dioxide was measured using the steady state method. 
Desatu ration was defined as a decrease in oxygen saturation from the baseline 
Sa0 2 of more than 4%. The baseline Sa0 2 was defined as the mean saturation 15 min 
before sleeping, lying in the horizontal position. Statistical analyses were performed 
with the Wilcoxon test and with the Spearman regression analysis, ρ values of 0.05 or 
less were considered significant. 
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Table 2.1 Daytime characteristics 
Age (years) 
FEV, (% predicted) 
IVC (% predicted) 
TLC (% predicted) 
FRC (% predicted) 
RV (% predicted) 
HCVR (liters/min/kPa) 
РаО
г
 (kPa) 
PaC02 (kPa) 
All patients (SD) 
(52 M, 8 F) 
67.4 (7.4) 
34.2 (11) 
80.1 (17) 
99.1 (21) 
129.0 (33) 
141.6 (41) 
3.9 (3.7) 
9.0 (1.5) 
5.7 (1.0) 
Monde saturators 
(13 M, 0 F) 
70.3 
40.4 
83.8 
101.9 
126.7 
138.1 
6.0 
9.4 
5.5 
Desaturators 
(39 M, 8 F) 
66.6 
32.5* 
79.1 
98.3 
129.9 
142.5 
3.3Γ) 
8.9 
5.8 
* ρ < 0.05,(*) ρ - 0.06 
HCVR: Hypercapnic ventilatory response 
2.4. Results 
2.4.1. Nocturnal oxygen desaturations 
Forty-seven of the 60 patients (78%) developed one or more episodes with desatura­
tions during their sleep. The mean nocturnal saturation of these patients was 88.5% 
(range, 69%-96%). The mean, median and modal nocturnal oxygen saturation values 
did not differ significantly from each other. The mean value of the lowest Sa02 was 
77.8% (range, 48%-90%). 
The daytime characteristics of the desaturating and nondesaturating patients are 
shown in Table 2.1. The desaturators had a significantly lower FEV, and a lower 
hypercapnic ventilatory response than the nondesaturators. Table 2.2 shows correla­
tions of several nocturnal saturation data with the daytime measurements. Although all 
correlations were significant, even the highest correlation between awake Pa02 and 
mean nocturnal Sa02 explains only 62% of the variation in nocturnal Sa02. 
2.4.2. Association of breathing disorders with nocturnal desaturations 
Almost all of the episodes with desaturations during the sleep were associated with 
disordered breathing; 83% hypopnoea and 16.5% apnoea. The predominant type of 
breathing disorder was central hypoventilatbn/hypopnoea and occurred mostly during 
the REM stage. If apnoeas occurred, the obstructive type was the most common. 
Of the sleeping time 15.2% was spent in the REM stage and 61.4% of the total 
REM time was spent desaturated, which contained 47.9% of all the desaturations. 
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Table 2.2 Correlation coefficients between the nocturnal Sa0 2 data and daytime 
measurements 
Sa02 Pa02 РаСОг HCVR (%) (kPa) (kPa) (liters/min/kPa) 
Mean nocturnal ЗаО
г
 (%) 
SD of mean Sa0 2 (%) 
Lowest Sa0 2 (%) 
Maximal drop (%) 
0.7B 
-0.50 
0.62 
-0.49 
0.79 
-0.52 
0.65 
-0.42 
-0.57 
0.50 
-0.61 
0.52 
0.40 
-0.53 
0.48 
-0.34 
All coefficients are significant (p < 0.001) 
HCVR: Hypercapnic ventilatory response 
2.5. Discussion 
2 . 5 . 1 . Nocturna l o x y g e n desaturat ions 
The results confirm that falls in oxygen saturation during sleep are common in patients 
with COPD. At a group level there is a strong correlation between the nocturnal 
saturation data and the daytime Sa02, Pa0 2 l РаСОг, and the ventilatory C 0 2 
response. However, even the best correlation seems too weak to predict nocturnal 
saturation precisely enough, to be clinically useful for the individual patient. Since, for 
instance, patients with a daytime Sa0 2 of 95% may develop a mean nocturnal Sa0 2 
varying from 86% to 93% (fig 2.1). 
Furthermore, the correlation between the mean nocturnal Sa0 2 and the hypercapnic 
ventilatory response seems equivocal. This correlation shows that patients with a low 
hypercapnic ventilatory drive may or may not develop desaturations during their sleep, 
whereas patients with a high hypercapnic drive are very unlikely to desaturate during 
the night. These correlations are consistent with the results of others (6). The differ­
ence in mean ventilatory СО
г
 response which is found between the desaturators and 
the nondesaturators is consistent with this correlation. 
There is a significant difference in FEV, values between the desaturators and the 
nondesaturators. Probably, the bronchial obstruction will cause the sooner and more 
severe alveolar hypoventilation and an increased ventilation perfusion mismatching. 
Furthermore, the starting position of the oxygen dissociation curve will also affect the 
frequency and severity of the desaturations. 
2.5.2. Association of breathing disorders with nocturnal desaturations 
The main cause of the desaturating episodes during sleep seems to be central 
hypoventilation during the REM sleep stage. Apnoeas only play a minor role. This is 
consistent with the results of others (1,3,4,5). Central hypopnoea/hypoventilation can 
be explained by physiological changes during the REM sleep stage, such as the 
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reduced intercostal muscle activity and the reduced chemical drives in combination with 
the disability of the diaphragm of COPD patients to compensate. Guiiieminault found 
sleep apnoea in 84% of his patient group. These patients were selected from a sleep 
disorders clinic, and suffered only from a mild pulmonary disease (2). 
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Figure 2.1 Correlation between mean nocturnal Sa02. Blank dots, desaturating patients; black 
dots, nondesaturating patients. 
2.6. Conclusion 
It is concluded that low daytime SaOJ Pa02 values, high daytime PaC02 values, low 
hypercapnic ventilatory drives, and low FEV, values in COPD patients are correlated 
with desaturations during sleep. But none of the daytime indicators is able to predict 
the nocturnal saturation precisely enough to be clinically useful. Therefore, overnight 
recordings will remain necessary. 
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3.1. Abstract 
A first-night effect in EEG variables has been shown in polysomnographies of normal 
subjects. It is conceivable that this holds for patients with chronic obstructive pulmon-
ary disease (COPD) as well. However, not much is known about the impact of the first-
night effect on the nocturnal oxygen saturation and breathing in patients with COPD. 
Hence, is it necessary to perform duplicate nocturnal studies if one aims to study the 
oxygen saturation and breathing pattern? Therefore, fifteen patients with COPD were 
studied on two consecutive nights, and in sixteen other COPD patients studies were 
performed on two nights one week apart. 
The mean nocturnal Sa02 of the patients studied on two consecutive nights was 
89% (SD 5.6) in the first night and 89% (SD 4.9) in the second. In the group studied 
on two non-consecutive nights, the mean nocturnal Sa02 value was 86% (SD 4.3) and 
87% (SD 3.1) respectively. No significant difference was found in disordered breathing 
of the first and second night in both situations. 
It is concluded that a single night's recording is sufficient to describe the nocturnal 
oxygen saturation and breathing pattern in COPD patients. 
Keywords; Chronic obstructive pulmonary disease, first-night effect, nocturnal hypoxae-
mia. 
3.2. Introduction 
Studies in normal subjects show a variability in Polysomnographie EEG parameters 
between two nights of sleep. On the first night, less time is spent asleep, less time in 
the rapid-eye-movement (REM) sleep state and REM latency is prolonged, probably 
because of unfamiliarity with the surroundings and the equipment (1-4). On the other 
hand, the sleep deprivation of the first night may cause changes in the quantity and 
quality of the second consecutive night's sleep (5). 
Patients with chronic obstructive pulmonary disease (COPD) may develop oxygen 
desaturations during sleep, predominantly during the REM sleep state, due to dimin-
ished ventilation from reduced intercostal- and accessory-muscle activity and possibly 
reduced central drive (6, 7). Not much is known about the possible impact of the 
experimental situation, and of the night-to-night sleep stage variability on the nocturnal 
oxygen saturation and breathing pattern in COPD patients. One study in nine patients 
with COPD has shown that the mean and lowest saturation data on consecutive nights 
are very similar (7). Another study in COPD patients has reported no significant 
differences in oxygen saturation and breathing data during two non-consecutive nights 
(8). Nevertheless, it is still a common procedure in overnight research studies in COPD 
patients to use an acclimatization night (9-11). 
In the present study, nocturnal oxygen saturation and breathing movements were 
recorded. The results of two consecutive nights as well as those of two non-consecu-
tive nights were compared. This allowed conclusions about the necessity to perform 
duplicate studies in research aiming at information about the nocturnal saturation and 
breathing patterns in patients with COPD. 
39 
3.3. Methods 
3.3.1. Patients 
Thirty-one patients, 24 men and 7 women, with chronic obstructive pulmonary disease, 
as defined by the American Thoracic Society, participated in this study (12). In fifteen 
patients studies were performed on two consecutive nights. The other 16 patients were 
studied on two nights one week apart. Only patients with FEV, values less than 65% 
of the predicted value (13) and with a weight below 125% of the ideal weight were 
included. At the time of the study all patients were in a stable clinical state and 
optimally treated. None of them received benzodiazepines or other sedatives. The 
characteristics of the patients are shown in table 3.1. Each subject was well acquainted 
with the nursing staff and to the ward because of admissions in the past. Informed 
consent was given, and the study was approved by the Hospital Ethics Committee. 
Mean Range 
64 
29 
78 
101 
134 
142 
Θ.2 
6.1 
41-78 
18-52 
50-104 
65-149 
72-207 
84-291 
6.2-11.6 
4.4-7.7 
Table 3.1 Characteristics of the patients 
Age (years) 
FEV, (% predicted) 
IVC (% predicted) 
TLC (% predicted) 
FRC (% predicted) 
RV (% predicted) 
PaOj daytime (kPa) 
PaCOj daytime (kPa) 
3.3.2. Techniques and protocol 
Arterial oxygen saturation was measured with a pulse-ox ¡meter (Oxyshuttle, Sensor-
Medics). Thoracoabdominal movement was recorded by inductive plethysmography 
(Vitalog). Two thermistors were used to detect the oro-nasal airflow. An integrated 
electromyogram of the intercostal muscles was recorded to facilitate the detection of 
hypopnoea/hypoventilation. Therefore two surface electrodes were placed in the 
second and third intercostal space. The rectified and integrated EMG-activity of the 
intercostal muscles could indicate breathing efforts. In addition, the electrooculogram 
(EOG) was measured with surface electrodes. All signals were recorded on an ink 
writing recorder (Kipp BD101, Delft, The Netherlands). 
All patients slept in a darkened quiet single bedroom. The next morning they were 
asked to answer three questions: how was your sleep quality, sleep latency and how 
often did you wake up. 
The nocturnal oxygen saturation data were digitized and analysed by a computer 
(Apple lie) to provide a histogram with the mean and towest saturation of each night, 
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as well as the standard deviation of the mean saturation. Desaturation was defined as 
a decrease of more than 4% in oxygen saturation from the baseline Sa02. The 
baseline Sa0 2 was defined as the mean saturation 15 minutes after falling asleep. The 
total desaturation time was calculated. 
Disorders of breathing were judged by interpreting the signals of the oro-nasal 
airflow, the thoracoabdominal movement, the activity of the intercostal muscles and the 
oxygen saturation all together. Central apnoea was defined as a cessation of airflow, 
thoracoabdominal movement and activity of the intercostal muscles for at least 10 
seconds. Obstructive apnoea was defined as an absence of airflow for at least 10 
seconds in the presence of thoracoabdominal movement and intercostal muscle 
activity. Central hypopnoea/hypoventilation was defined as a decrease in airflow, 
thoracoabdominal movement and intercostal muscle activity, accompanied by a 
desaturation. Obstructive hypopnoea was defined as a decrease in airflow, with 
unchanged or increased thoracoabdominal movement and/or increased intercostal-
muscle activity, together with a desaturation. 
Regular rapid EOG activity and absence of gross body movements as shown in the 
EMG were considered to indicate REM sleep. Absence of orbicularis oculi-EMG-
activity, absence of gross body movements and presence of a regular breathing 
pattern were used as an indication of the transition of awake state into sleep. 
The data were analysed by means of the paired t-test or where necessary the 
Wilcoxon signed rank test was used, ρ values of 0.05 or less were considered 
significant. 
3.4. Results 
The mean values of the nocturnal oxygenation parameters of the groups are shown in 
table 3.2. No significant differences were assessed by paired comparison in any of the 
oxygen saturation parameters of the two consecutive and of the two non-consecutive 
nights. Limited individual variation was found, which is shown in table 3.3. 
Table 3.2 Nocturnal saturation parameters (SD) 
Mean Sa0 2 (%) 
Lowest Sa0 2 (%) 
Desaturation time (min) 
Consecutive 
1st 
89 (5.6) 
80(11) 
32 (93) 
nights 
2nd 
89 (4.9) 
80 (12) 
33 (95) 
Non-consecutive nights 
1st 2nd 
86 (4.3) 
75 (5.5) 
41 (39) 
87 (3.1) 
73 (6.6) 
43(37) 
None of the differences was significant 
Twenty-six patients (84%) developed nocturnal desaturations. In 24 of them (92%) 
most desaturations (80 to 91%) were accompanied by central hypoventilation and 
occurred predominantly in association with regular rapid eye movements on both 
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Table 3.3 Individual mean nocturnal saturation data (SD) (%) 
Patients 1-15 slept on two consecutive nights 
Patients 16-33 slept on two non-consecutive nights 
Nr Mean Sa02 Nr Mean Sa02 Nr Mean 8аОг Nr Mean Sa02 
1 
1 
2 
2 
3 
3 
4 
4 
5 
5 
6 
6 
7 
7 
θ 
β 
93.6 
92.9 
87.5 
88.8 
90.7 
90.8 
86.2 
85.7 
90.7 
91.9 
91.4 
91.3 
94.1 
94.5 
91.5 
90.5 
(1.1) 
(1.0) 
(2.5) 
(2.7) 
(2.0) 
(1.3) 
(2.7) 
(3.0) 
(2.3) 
(1.9) 
(1.3) 
(1.2) 
(0.9) 
(1.1) 
(1.5) 
(2.0) 
9 
9 
10 
10 
11 
11 
12 
12 
13 
13 
14 
14 
15 
15 
90.6 
88.5 
85.2 
86.7 
91.0 
88.5 
88.8 
89.3 
88.5 
87.3 
70.9 
73.5 
93.7 
92.2 
(6.3) 
(5.1) 
(1.5) 
(1.2) 
(1.7) 
(1.9) 
(2.7) 
(1.9) 
(2.3) 
(2.5) 
(8.2) 
(9.6) 
(1.2) 
(1.6) 
16 
16 
17 
17 
18 
18 
19 
19 
20 
20 
21 
21 
22 
22 
23 
23 
85.5 
83.1 
78.2 
83.1 
91.8 
92.6 
86.4 
85.2 
89.8 
88.1 
86.7 
88.5 
86.9 
86.2 
91.5 
91.2 
(2.7) 
(3.8) 
(3.8) 
(3.9) 
(2.0) 
(2.1) 
(4.7) 
(4.3) 
(4.5) 
(3.0) 
(3.3) 
(3.3) 
(2.8) 
(3.0) 
(2.6) 
(3.2) 
24 
24 
25 
25 
26 
26 
27 
27 
28 
28 
29 
29 
30 
30 
31 
31 
85.2 
85.3 
89.1 
90.1 
88.3 
87.9 
88.7 
89.1 
88.5 
89.1 
84.4 
85.3 
86.9 
86.9 
83.5 
82.5 
(2.7) 
(6.2) 
(2.1) 
(2.1) 
(2.3) 
(2.3) 
(2.8) 
(3.0) 
(2.0) 
(2.0) 
(2.2) 
(3.2) 
(2.4) 
(2.6) 
(2.9) 
(3.9) 
nights. In the group of patients who were studied on two consecutive nights, 15% of 
the desaturations in the first night was associated with obstructive apnoeas or hypo-
pnoeas and 20% in the second night (p >0.05). For the patients who slept on two non-
consecutive nights the percentages were 8.8 and 9.1 respectively. In two (number 9 
and 14) of the 26 patients with desaturations, the desaturation pattern consisted of 
series of short oscillatory dips due to obstructive apnoeas and hypopnoeas which 
occurred during REM and NREM sleep. These two patients developed an obstructive 
sleep apnoea/hypopnoea index (number of apnoeas and hypopnoeas per hour) above 
5, on both nights. Their apnoea/hypopnoea index varied from 7 and 61 respectively in 
the first night to 9 and 59 in the second. All other patients had a sleep 
apnoea/hypopnoea index below two, on both nights. During the two nights no shift was 
seen from predominantly obstructive to central disordered breathing or vice versa. 
The subjective sleep quality did not differ significantly between the two consecutive 
nights (table 3.4). In the patients who slept on two non-consecutive nights, eight 
patients reported that they had more difficulties falling asleep in the second night. 
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Table 3.4 Numbers of patients reporting subjective sleep quality 
2nd consecutive night 2nd non-consecutive night 
better worse same better worse same 
Sleep quality 6 2 7 4 5 7 
Sleep latency 5 0 10 2 Θ* 6 
Awakenings 7 2 6 8 5 3 
* ρ < 0.05 
3.5. Discussion 
In this study the mean and the lowest saturation of the patient groups showed no 
significant difference between two consecutive or two non-consecutive nights. Yet, for 
the individual patient a variability could be shown. These night-to-night shifts could 
occur in either direction (a decrease or increase) and moreover, the individual variation 
of two consecutive nights was comparable to that of two non-consecutive nights. 
Therefore, we conclude that there is no reason to consider the second night more 
appropriate to characterise the oxygen saturation pattern in COPD patients. Further­
more, the variation appeared to be quite small. The largest change was seen in one 
patient with a baseline Sa0 2 on the steep part of the oxygen hemoglobin dissociation 
curve, which means that probably the change in Pa02 was not larger than that of 
others. Practically these results imply thai if for instance a threshold of 90% would be 
taken as the criterion for oxygen supplementation, a one night's recording would 
inappropriately withhold nocturnal oxygen therapy in two out of the 31 (6%) patients. 
Five out of 31 patients (16%)(number 1, 3, 6, 7, 11 of table 3.3) did not develop 
any desaturations in the first night or in the second night in spite of indications of REM 
sleep. In three of these patients desaturations probably did not occur because their 
initial baseline Sa0 2 was high. The desaturation time of the other 26 patients could 
increase on the second consecutive and non-consecutive night by 34 and 38 minutes 
or decrease by 44 or 11 minutes respectively. This considerable variation in desatura­
tion time had hardly any effect on the mean saturation data, presumably because 
desaturation time is defined as crossing a certain threshold and large differences in 
desaturation time are therefore possible with small shifts in Sa02. 
Little variation was seen in disordered breathing during the two nights. A study in 
COPD patients and a study in healthy older persons (66.1 years) showed similar 
results (4, 8). 
A first-night effect is evident from EEG parameters (1-4) and it is conceivable that 
this may hold for COPD patients as well. The patients in this study were accustomed 
to the ward and the nursing staff which might have partly reduced the first-night effect 
(4, 14, 15). However, this night-to-night sleep stage variability apparently did not 
substantially affect the breathing and saturation pattern in this group of patients with 
COPD. Therefore it is concluded that in COPD patients a single night's recording is 
sufficient to characterise their nocturnal oxygen saturation and breathing patterns. 
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4.1. Abstract 
In the current study in 42 normoxic or mildly hypoxic COPD patients (daytime Pa02 
above 8 kPa) the prediction of the occurrence of nocturnal hypoxaemia from daytime 
parameters was studied. Nocturnal hypoxaemia was defined as a mean oxygen 
saturation (Sa02) below 90%. Detection of these patients seems clinically relevant 
since nocturnal hypoxaemia may be a predecessor of pulmonary hypertension. In ten 
out of 42 patients enough desaturations occurred to develop nocturnal hypoxaemia. 
These ten patients were significantly younger, had a lower daytime Pa02, higher 
PaC02 and a lower steady-state hypercapnic ventilatory response. Furthermore, 
significantly more patients with nocturnal hypoxaemia smoked and complained about 
daytime sleepiness. Multiple linear regression analysis demonstrated that only daytime 
Pa02 and the hypercapnic ventilatory response contributed to the prediction of the 
mean nocturnal Sa02. In this study patients with a high daytime Pa02 (> 11 kPa) did 
not develop nocturnal hypoxaemia. In order to avoid redundant sleep studies, the 
value of the hypercapnic ventilatory response as a screening parameter was exam­
ined in all patients with a Pa02 between 8 and 11 kPa. Therefore, in the remaining 
patients the hypercapnic ventilatory response was used to distinguish nocturnal 
hypoxaemic from normoxaemic patients. Only patients with a low response (<3.5 
l/min/kPa) were considered to run a risk of developing nocturnal hypoxaemia. The 
sensitivity of this test was 80% and the specificity 70%. It was concluded that measur­
ing the hypercapnic ventilatory response was helpful to find patients with possible 
nocturnal hypoxaemia. 
4.2. Introduction 
Oxygen desaturations during sleep may occur in patients with chronic obstructive 
pulmonary disease (COPD)(1). In hypoxaemic COPD patients, nocturnal desaturations 
will already be treated adequately when long-term supplemental oxygen is prescribed 
(2). Yet, COPD patients with mild daytime hypoxia or normoxia (Pa02 > 8 kPa) may 
have transient oxygen desaturations during sleep as well, but they will not attract the 
attention of physicians who only evaluate daytime blood gas values (3, 4). Neverthe­
less, this transient nocturnal hypoxaemia is clinically important since it is accompanied 
by increases of the pulmonary artery pressure (5-11). Moreover, it has been suggested 
that these transient elevations of the pulmonary artery pressure may lead to sustained 
pulmonary hypertension and finally to the development of cor pulmonale (8, 12-14). 
Fletcher et al have demonstrated that of a group of 135 COPD patients with a 
daytime Pa02 above 8 kPa, 37 (27%) desaturated below 90 per cent for five minutes 
or more, reaching a lowest 8аО
г
 of at least 85% (3). Practically, it is not feasible to 
perform expensive sleep studies in all COPD patients who are mildly hypoxic or 
normoxic while awake. Therefore it has been investigated whether daytime characteris­
tics predict oxygenation during sleep in these patients. Fletcher et al have shown that 
the desaturators had lower awake Pa02 and higher PaC02 values than nondesatura-
tors, but these parameters appeared to be of little predictive value (3). Bradley et al 
have indicated that daytime hypercapnia is a risk factor for the development of 
nocturnal hypoxaemia in COPD patients with mild daytime hypoxaemia (4). 
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In the current study the value of daytime parameters to predict nocturnal hypoxae-
mia, defined as a mean nocturnal Sa02 below 90%, is established in COPD patients 
with mild hypoxia or normoxia during the day (РаО
г
 >8 kPa). 
4.3. Methods 
4.3.1. Patients 
Forty-two COPD patients, with chronic obstructive pulmonary disease as defined by the 
American Thoracic Society participated in this study (2). Inclusion aiteria were: a 
daytime Pa02 above 8.0 kPa and a FEV, value less than 65% of the predicted value (15). The patient characteristics are shown in Table 4.1. All patients were in a stable 
clinical condition and received optimal bronchodilatory treatment. The medication was 
continued, except benzodiazepines. Each subject gave informed consent. The study 
was approved by the Hospital Ethics Committee. 
Table 4.1 Characteristics of the COPD patients (mean (SD)) 
All patents Mean nocturnal 
Sa0 2 < 90% 
Mean nocturnal 
Sex 
Age (yrs) 
FEV, (% predicted) 
IVC (% predicted) 
TLC (% predicted) 
FRC (% predicted) 
RV (% predicted) 
HCVR (l/mm/kPa) 
РаО
г
 daytime (kPa) 
PaC02 daytime (kPa) 
Body mass index 
Smoking (%) 
Sleepiness (%) 
Mean nocturnal Sa0 2 
Lowest nocturnal SaO. 
* ρ < 0 05 
(*) 0.1 < ρ < 0 05 
(%) 
2 (%) 
39 M, 3 F 
67 (7) 
35 (10) 
80 (17) 
100 (22) 
131 (32) 
146 (43) 
4.2 (4) 
9.8 (1.1) 
5.4 (0.7) 
23 (3) 
24 
24 
91.3 (2.3) 
83 3 (6 7) 
HCVR: Нур гсаршс ventilatory response 
Ю М 
66 (6) 
31 (10 
71 (17) 
98 (32) 
140 (46) 
163 (65) 
2.1 (2) 
9.1 (0.7) 
5.8 (0.9) 
23 (4) 
50 
60 
88.2 (1.8) 
77.7 (5.7) 
29 M , 3 F 
68 (7) * 
36 (11) 
82 (17) 
100 (18) 
128 (26) 
141 (33) 
4.9 (4.2) * 
10.0 (1.1) * 
5.3 (0.6) (*) 
23 (3) 
16 (*) 
12 
92.2 (1.5) * 
85.1 (5.9) * 
4.3.2. Techniques and protocol 
During the day arterial blood gas samples were obtained and pulmonary function 
parameters were determined. The ventilatory response to carbon dioxide was 
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measured using the steady-state method (16). The patient was connected to a closed 
spirometrie circuit by means of a mouth piece. The end-tidal PCO, level could be 
increased by adjusting a three-way valve, partially short-circuiting the C0 2 absorber in 
the inspiratory limb of the dicuit. The oxygen saturation level was maintained by 
adding oxygen to the system. Furthermore the patients were questioned about the 
number of cigarettes they smoked and about daytime sleepiness. The answer to the 
latter question was scored "yes" if the sleepiness interfered with daily life or if people 
noticed their sleepiness. 
During the night, the oxygen saturation, chest-wall movements, oro-nasal airflow, 
etectromyogram of the Intercostal muscles and the electrooculogram were recorded 
from 10 p.m. until 6 a.m. Arterial oxygen saturation was measured with a pulse-
oximeter (Oxyshuttle, SensorMedics). Thoracoabdominal movement was recorded by 
inductive plethysmography (Vitalog). Two thermistors were used to detect the oro-nasal 
airflow. An electromyogram of the 2nd and 3rd parasternal intercostal muscles was 
recorded with surface electrodes to facilitate the detection of hypopnoea/hypoventila-
tion. The rectified and integrated EMG-activity of the intercostal muscles indicated 
breathing efforts. In addition the electrooculogram was measured. 
The saturation data of the whole night were stored, digitized and analysed by a 
computer (Apple Me) to provide the mean and the lowest saturation of each night. 
Desaturation was defined as a decrease of more than 4% in oxygen saturation from 
the asleep baseline Sa02. The asleep baseline Sa02 was defined as the mean 
saturation 15 minutes after falling asleep, lying in a horizontal position. Nocturnal 
hypoxaemia was defined as a mean Sa02 below 90%. 
Disorders of breathing were assessed by interpreting the signals of the oro-nasal 
airflow, the thoracoabdominal movement, the activity of the intercostal muscles and the 
oxygen saturation all together. Central apnoea was defined as a cessation of airflow, 
thoracoabdominal movement and activity of the intercostal muscles for at least 10 
seconds and obstructive apnoea as absence of airflow for at least 10 seconds in the 
presence of thoracoabdominal movement and intercostal muscle activity. Central 
hypopnoea/hypoventilatbn was defined as a decrease in airflow, thoracoabdominal 
movement and intercostal muscle activity, accompanied by a desaturation. Obstructive 
hypopnoea was defined as a decrease in airflow, with unchanged or increased 
thoracoabdominal movement and/or increased intercostal muscle activity, in conjunc-
tion with a desaturation. 
Patients were considered to be in the REM sleep state when regular EOG activity 
was present. 
Statistical analyses for paired comparisons were performed using the signed rank 
test. Relations between variables were evaluated with Spearman rank's correlation. 
Furthermore, partial correlations were determined by multiple linear regression 
analysis. 
4.4. Results 
In 33 of the 42 patients (79%) one or more nocturnal desaturations occurred. Eighty-
five per cent of the desaturations was associated with central hypoventilation and 
accompanied by rapid-eye-movements. In one patient more than 10 obstructive 
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apnoeas per hour were found. In ten out of the 42 patients (24%) the occurrence of 
desaturations resulted in a mean nocturnal oxygen saturation level below 90%. These 
ten patients were significantly younger and had lower daytime РаО
г
 values, higher 
PaC02 values and lower hypercapnic ventilatory responses than the 32 others (table 
4.1). Furthermore, among the patients with nocturnal hypoxaemia there were signifi­
cantly more smokers and more patients complained about daytime sleepiness com­
pared to the group without nocturnal hypoxaemia. No patients with a daytime Pa0 2 
above 11.0 kPa developed a mean hypoxaemic level during the night. Age, daytime 
Pa0 2 and PaC02 showed such a large overlap that it was not possible to distinguish 
between patients with and without nocturnal hypoxaemia. The value of the hypercapnic 
ventilatory response to separate the nocturnal hypoxaemic and normoxaemic group 
was examined in the remaining patients with a daytime Pa02 below 11.0 kPa. A cut-off 
point for the hypercapnic ventilatory response of 3.5 l/min/kPa was calculated to give 
the highest sensitivity in the prediction of nocturnal hypoxaemia. The results of the 
hypercapnic ventilatory response as a screening test are shown in table 4.2. The 
sensitivity of this test was 80% and the specificity 70%. The negative predictive value 
was 9 1 % and the positive predictive value 50%. 
Table 4.2 Results of the hypercapnic ventilatory response (HCVR) as a screening 
method to distinguish patients with nocturnal hypoxaemia (mean Sa0 2 < 
90%: positive test) and without nocturnal hypoxaemia (mean Sa0 2 £ 90%: 
negative test). Patients with a HCVR below 3.5 l/min/kPa were considered 
to be prone to nocturnal hypoxaemia. 
Real mean Sa02 < 90% 
Real mean Sa02 i 90% 
Predicted as Predicted as 
mean Sa02 < 90% mean Sa02 i 90% 
8 2 
8 19 
16 21 
10 
27 
Two patients were falsely classified as not having nocturnal hypoxaemia. Eight patients were 
falsely classified as having nocturnal hypoxaemia. 
Table 4.3 Correlations between the mean nocturnal Sa0 2 and daytime characteristics 
Mean nocturnal Sa02 
SaO, 
daytime 
(%) 
0.56* 
Pa02 
daytime 
(kPa) 
0.58* 
HCVR 
(l/min/kPa) 
0.41* 
Number of 
cigarettes 
-0.49* 
Sleepiness 
-0.45* 
* ρ < 0.05 
HCVR: Hypercapnic ventilatory response 
None of the other daytime parameters was significantly correlated 
50 
Spearman rank's correlation showed a significant relation between the mean nocturnal 
Sa0 2 and daytime Sa02, daytime РаОг, the hypercapnic ventilatory response, pres­
ence of sleepiness and number of cigarettes smoked (table 4.3). The partial correla­
tions to the prediction of the mean nocturnal Sa0 2 were determined by multiple linear 
regression analysis. The hypercapnic ventilatory response was arbitrarily scored as 
"one" if the response was й 3.5 1/min/kPa and as "two" if the value was > 3.5 |/min/kPa. 
The results showed that only daytime Pa02 (32%) and the hypercapnic ventilatory 
response score (5%) contributed independently to the total variance of 37% of the 
mean nocturnal 5аО
г
. The prediction equation was: Mean nocturnal S a 0 2 - 79.07 + 
1.07 Pa0 2 + 1.1 response score (z - a + bx + cy). 
4.5. Discussion 
It has been suggested that nocturnal hypoxaemia is a predecessor of pulmonary 
hypertension (8, 12-14). Pulmonary hypertension is a progressive disease that starts 
with constriction due to hypoxia and ends finally in structural histologic changes (17). 
Treatment with oxygen suppletion can partly reverse the pulmonary hypertension in 
hypoxaemic COPD patients (18, 19). If the oxygen treatment is started in an earlier 
phase of the disease, as in normoxaemic COPD patients with nocturnal hypoxaemia, 
the development of pulmonary hypertension can perhaps be prevented or delayed. In 
this perspective, detection of nocturnal hypoxaemia seems clinically important. 
In the current study nocturnal hypoxaemia was defined as a mean nocturnal Sa0 2 
below 90%. It was indicated that an oxygen saturation level below 90% increases the 
pulmonary pressure to a critical level (20). Furthermore, mean nocturnal hypoxaemia 
was considered to be clinically more relevant than the occurrence of short desatura-
tions themselves, since it is hypoxaemia that is related to pulmonary hypertension and 
secondary polycythemia and not the desaturations (1, 21-23). 
An attempt was made in this study, to find daytime characteristics which could 
predict nocturnal hypoxaemia in COPD patients with a daytime РаО
г
 above 8.0 kPa, 
in order to avoid the performance of redundant sleep studies in the future. In ten of the 
42 (24%) patients enough desaturations occurred to result in a mean nocturnal 
hypoxaemia. The group of patients with and without nocturnal hypoxaemia had a 
significantly different age, Ра02-, РаСОг value, hypercapnic ventilatory response, 
smoking habits and complaints of daytime sleepiness. Data derived by multiple linear 
regression showed that only daytime РаО
г
 and the hypercapnic ventilatory response 
contributed to the precise prediction of the mean nocturnal Sa02. In patients with high 
daytime Pa0 2 values, short desaturations may occur, but it is very unlikely that they 
develop a mean hypoxaemic level during the night. In our group of patients no one with 
a Pa0 2 above 11.0 kPa had nocturnal hypoxaemia To distinguish the other patients 
into those with and those without nocturnal hypoxaemia, the hypercapnic ventilatory 
response, measured by the steady-state method, was used. If sleep studies were 
performed only in those patients with a hypercapnic ventilatory response below 3.5 
l/min/kPa, 2 of the nocturnal hypoxaemic patients (20%) would be missed whereas 8 
of the nocturnal normoxb patients (22%) would be measured unnecessarily. One of the 
two patients with unexpected nocturnal hypoxaemia had an obstructive sleep 
apnoea/hypopnoea syndrome. The negative predictive value (defined as the true 
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negatives, divided by the number of true and false negatives) of the test as a screen­
ing method in the current study was 91%, which is quite reasonable. Yet, only a small 
number of patients participated in this study and the cut-off point for the hypercapnic 
ventilatory response had a low positive predictive value (50%)(defined as the true 
positives, divided by the number of true and false positives). The effectiveness of the 
test still has to be established in a prospective study. Nevertheless, it appeared that 
patients with higher C02 responses were not likely to develop nocturnal hypoxaemia, 
whereas patients with lower ventilatory responses to C02 might or might not have 
nocturnal hypoxaemia. These results are similar to those demonstrated in hypoxic 
COPD patients (24, 25). It suggests that a blunted chemical drive by itself does not 
necessarily cause the nocturnal hypoxaemia, but allows the hypoxaemia, which is 
caused by other factors, to persist. Other parameters, not measured in this study, but 
possibly influencing the nocturnal saturation are for instance respiratory muscle 
performance and hypoxic ventilatory drive. 
The results of this study imply some practical considerations. Firstly, nocturnal 
hypoxaemia in patients with a daytime Pa02 above 11.0 kPa is very unlikely. Secondly, 
in COPD patients with a daytime Pa02 below 11.0 kPa and above 8.0 kPa, measure­
ment of the hypercapnic ventilatory response may be helpful as a screening test; only 
in patients with low responses sleep studies are indicated. 
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5.1. Abstract 
In this study, the end-tidal PC02during the night was measured instead of recording 
the oro-nasal airflow with thermistors. The P^COj signal was obtained by introducing 
a cannula through the nose into the naso-pharygeal cavity. 
The usefulness of this method to identify nocturnal hypoventilation was studied in 
29 patients with chronic obstructive pulmonary disease (COPD) with and without 
oxygen supplementation. The results showed that 27 patients with COPD developed 
67 nocturnal oxygen desaturations which were all accompanied by raised PE TC02. 
During oxygen therapy in all COPD patients nocturnal episodes with increased P^COj 
occurred. 
Furthermore, the detection of nocturnal apnoeas and hypopnoeas was assessed in 
19 subjects who were referred to the sleep laboratory for snoring and daytime sleepi­
ness. In this group episodes of disordered breathing could easily be assessed. The 
P E T C0 2 signal was especially useful to identify hypopnoes which were accompanied by 
only small dips in Sa0 2 (<3%). 
It is concluded that Р
вг
СО
г
 measurement is useful in the detection of hypoventila­
tion during sleep in COPD patients, especially when they receive supplemental oxygen. 
P E T C0 2 recording detects apnoeas and hypopnoeas in patients with OSA and is 
especially helpful to identify hypopnoeas which are accompanied with only small dips 
in oxygen saturation. The method seems favourable to oro-nasal airflow recording and 
is of complementary value to oximetry and measurement of breathing movements. 
Keywords: chronic obstructive pulmonary disease, obstructive sleep apnoea syndrome, 
end-tidal PC02, nocturnal hypoventilation 
5.2. Introduction 
Patients with chronic obstructive pulmonary disease (COPD) may hypoventilate during 
sleep, which may lead to profound nocturnal oxygen desaturations (1). Oxygen 
supplementation in these patients aggravates the hypoventilation (2, 3). Patients who 
are suspected to have obstructive sleep apnoeas, may also show obstructive hypo­
pnoeas, which are clinically as important as apnoeas (4). 
Hypoventilation and hypopnoea during sleep are difficult to detect non-invasively. 
Usually the determination is limited to the interpretation of the oro-nasal airflow 
measured with thermistors and the thoracoabdominal movements recorded by inductive 
plethysmography. When the amplitude of one of these signals is reduced to half or 
one-third of its previous size, this is interpreted as hypoventilation. Yet, these signals 
allow only a qualitative or semi-quantitative indication of respiration (5-9). The thermis­
tors may touch the skin and heaten themselves, which influences the amplitude of the 
signal substantially (5). Hypoventilation and hypopnoeas will easily be missed (4, 10). 
Inductive plethysmography shows changes in calibration during the night due to 
changes in posture (5-9). It is therefore impossible to make deductions about possible 
hypoventilation from this type of recordings. Oxygen desaturations detected with 
oximetry may be helpful to indicate hypoventilation but is of considerably less use 
during oxygen supplementation. Furthermore, hypopnoeas may be accompanied with 
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just slight falls in Sa02 (3%), which make them difficult to detect by oximetry tracing. 
The gold standard for the definition of hypoventilation is an increase in arterial carbon 
dioxide tension (PaC02). Transcutaneous PC02 recording has the disadvantage of a 
very slow response to arterial PC02 changes (2, 5, 8, 11-13). This precludes the 
detection of short bouts of hypopnoea. Therefore, the transcutaneous method is not 
recommended in sleep studies (8). 
In this study continuous recording of the end-tidal PC02 during sleep is used. The 
method was used in 29 hypoxaemic patients with COPD, with and without oxygen 
supplementation. Furthermore in 19 patients who had a history of obstructive sleep 
apnoea/ hypopnoea syndrome (OSA), the occurrence of apnoeas and hypopnoeas was 
assessed. 
5.3. Methods 
5.3.1. Patients 
Twenty-nine hypoxaemic COPD patients, 21 men and 8 women, with stable chronic 
obstructive pulmonary disease, as defined by the American Thoracic Society, partici­
pated in this study (14). Their mean age ranged between 44 and 87 years (mean 67 
years). The FEV, varied from 15 to 48% (mean 31%) of the predicted value (15). They 
had no exacerbations in the four weeks prior to the study. Hypoxaemia was indicated 
by an arterial РО
г
 of 8.5 kPa or less measured on two different occasions, two to four 
weeks apart. The blood gas values of the whole group showed a mean РаО
г
 of 7.5 
kPa (range 5.2-8.5 kPa), and a mean PaC02 of 6.3 kPa (range 4.5-9.9 kPa). 
Furthermore, nineteen patients, 18 men and 1 woman, who had a history of 
obstructive sleep apnoea, based on the presence of snoring and daytime sleepiness, 
were studied. Their mean age was 48 years (range 34-66 years) and their mean body 
mass index was 27 (range 24-31). 
5.3.2. Techniques and protocol 
In all subjects the oxygen saturation, the end-tidal carbon dioxide tension, the thora­
coabdominal movements and the electrooculogram were measured during the night. 
The oxygen saturation was measured by a pulse-oximeter (Oxyshuttle, Sensor-
Medics). The P^COj was measured by introducing a flexible cannula (3 mm outer 
diameter) through the nose into the naso-pharygeal cavity and by connecting it via a 
perma-pure drying tube to a sampling capnograph (Mijnhart capnolyser). The awake-
and asleep- baseline Sa02 and P^COg were defined as the mean Sa02 and PETCOJ 
15 minutes before falling asleep and while sleeping respectively. Desaturation was 
defined as a decrease of more than 4% in oxygen saturation from the asleep baseline 
Sa02. Increased PETC02 was arbitrarily defined as a rise in Р^СОг of at least 0.3 kPa 
above the asleep baseline level. Furthermore, the highest PETCO,, during sleep was 
recorded. The PETC02 signal was analysed together with oxygen desaturations and 
breathing movements. No P^COj signal and thus no air movement for at least 10 
seconds, was considered to indicate apnoea. A desaturating episode accompanied by 
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an increased PETCOJ for at least 10 seconds was considered to be an indication for 
hypoventilation/hypopnoe. 
The breathing movements were measured with an inductive Plethysmograph around 
the thorax above the xyphoid (Vitalog and Respitrace). Apnoeas were considered to be 
central when the P^jCO^ and the thoracoabdominal movements were absent. Obstruc­
tive apnoeas were characterised by the absence of the Р^СОг signal and the pres­
ence of thoracoabdominal movements. In the context of this study, the detection of 
hypopnoeas and hypoventilation as such was the main objective. It is difficult to 
differentiate between obstructive and central hypopnoeas when only Р
Е
тСО
г
 and 
thoracoabdominal movements are recorded. Tentatively it was assumed that hypo­
pnoeas/ hypoventilation were obstructive if the respiratory movements remained 
unchanged or increased, and central when breathing efforts decreased. 
An electrooculogram was performed to distinguish sleep in the REM and the NREM 
sleep state. 
All subjects were studied from 10 p.m. until 6 a.m. in a quiet single room. They 
were allowed their usual medication, drinks and number of pillows. The patients with 
COPD were studied twice on consecutive nights during which they received, in random 
order, room air or oxygen 1 l/min through a nasal cannula, single blind. 
The signed rank test was used to determine statistical differences, ρ values of 0.05 
or less were considered to be significant. 
5.4. Results 
5.4.1. COPD patients 
The baseline oxygen saturation decreased 1 to 4% after falling asleep, whereas the 
P^COj showed a slight increase of 0.3 kPa on average (table 5.1). Twenty-six of the 
29 COPD patients developed a total number of 67 nocturnal oxygen desaturations. 
Seventy per cent of the desaturations occurred simultaneously with regular EOG 
activity indicating REM-sleep. All desat и rating episodes were accompanied by a rise 
in PEJCOJ and 3 of these episodes (5%) by obstructive apnoeas. Only one of the 29 
patients developed more than 10 obstructive apnoeas and hypopnoeas per hour. 
Thirty-five desaturating episodes (52%) were accompanied by a decrease of 50% 
in breathing movements, 8 (12%) with an increase and in 24 episodes (36%) no 
change in thoracoabdominal movements was shown. Figure 5.1 shows an example of 
a part of a nocturnal recording from a COPD patient during a desaturating episode with 
a concomitant elevation in the Р
ЕТ
СО
г
 signal. 
During oxygen supplementation the initial baseline Sa0 2 and РЕ1-СОг levels were 
elevated (table 5.1). The rise in PETCOJ during the night was significantly higher during 
oxygen supplementation than during the room air night (1.5 and 1.9 kPa respectively), 
whereas the fall in Sa0 2 was significantly lower (17 and 9% respectively). During 
oxygen supplementation all COPD patients developed episodes of raised P^-COj (> 
0.3 kPa) superimposed on the elevated asleep baseline P^COj. The mean time of 
extra elevations of the PETCOJ was 41 minutes (range 10-86). 
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Table 5.1 Nocturnal parameters of the COPD patients (N-29) and the subjects 
suspected of OSA (N-19) 
COPD 
without О
г
 with 0 2 
Subjects suspected of OSA 
whole group AHI>10 AHI<10 
(N-9) (N-10) 
Baseline Sa0 2 (%) 
Mean Sa0 2 (%) 
SD of mean Sa0 2 (%) 
Lowest Sa0 2 (%) 
Fall in Sa0 2 (%) 
Baseline PETCOJ 
awake (kPa) 
Baseline PE TC02 
asleep (kPa) 
Highest P^CO, (kPa) 
Rise PE TC02 (kPa) 
89 (3.8) 
86 (6.5) 
3.1 (1.3) 
72 (14) 
17 (11) 
5.2 (0.9) 
5.5 (0.9) 
6.7 (1.2) 
1.5 (0.8) 
94 (2.2)* 
92 (3.4)* 
2.6 (1.3) 
85 (7.3)* 
9 (7)* 
5.4 (0.8)* 
5.7 (0.9)* 
7.3 (1.3)* 
1.9 (0.8)* 
95 (1.3) 
93 (2.4) 
2.1 (1.6) 
86 (8) 
10 (7) 
4.8 (0.4) 
5.0 (0.4) 
5.8 (0.6) 
1.0 (0.5) 
95 (1.2) 
92 (3.0) 
2.9 (2.0) 
81 (9) 
13 (9) 
5.0 (0.4) 
5.2 (0.3) 
6.2 (0.4) 
1.2 (0.5) 
95 (1.4) 
94 (1.5) 
1.3 (0.4)* 
89 (4)* 
6 (3)* 
4.6 (0.5) 
4.9 (0.4) 
5.3 (0.5)* 
0.6 (0.65 
* ρ < 0.05; COPD patients with and without oxygen, and "OSA" patients with AHI>10 and <10 
AHI; apnoea-hypopnoea index 
SaOj wo 
(%) 
90 
«0 
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Figure 5.1 This nocturnal recording from a COPD patient shows a desaturating episode with a 
concomitant elevation in the PE TC02 signal which indicates hypoventilation. 
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5.4.2. OSA patients 
The nocturnal Sa0 2 and PETC02 values for the whole group are shown in table 5.1. In 
these subjects a slight decrease in baseline Sa0 2 (1 -2%) and an increase in baseline 
PCTCOJ ( k P a ) a f t e r falling asleep could be observed as well. In 11 of the 19 subjects 
desaturations (>4%) occurred, accompanied by obstructive apnoeas and hypopnoeas. 
The mean number of apnoeas per hour in these patients was 10 (range 0-39) and the 
mean number of apnoeas plus hypopnoeas per hour was 15 (range 1-59). In 18 
patients (95%) obstructive hypopnoeas occurred together with just small dips in Sa0 2 
of 2 to 3%. If these hypopnoeas were added, nine patients showed an 
apnoea/hypopnoea index (AHI) above 10 (range 11-62). 
The subjects were divided in those with an AHI above 10 and those with an AHI 
below 10 (table 5.1 ). The fall in nocturnal Sa02 as well as the rise in P E T C 0 2 during the 
night was significantly larger in the group with an AHI above 10. 
An example of a recording with obstructive apnoeas and one with obstructive 
hypopnoeas is shown in figure 5.2 and 5.3. 
5.5. Discussion 
In this study, Р
ЕТ
С02 is measured instead of oro-nasal airflow (by thermistors) for the 
detection of hypopnoeas and hypoventilation. By no means is PETCO,, considered to be 
representative of mean alveolar or arterial PC02. This holds especially for the patients 
with COPD since they have a large alveolar-arterial gradient and inequality of ventila­
tion. 
Seven of the 77 P E 1 C0 2 recordings were technically inadequate. In six COPD 
patients the tube clogged during the night and in the other case the tracing was 
disturbed by fluid in the COj-analyser. All subjects tolerated the application of the 
nasopharyngeal cannula well. 
In the COPD group nocturnal hypoventilation while breathing room air could easily 
be demonstrated. Every desaturation was accompanied by an increase in P E T C0 2 
indicating hypoventilation as the cause for the desaturation. An increased ventilation 
perfusion mismatching (increased shunt circulation) is an unlikely cause of the desa­
turation since this would be accompanied by a decreased P^-COj. Supplemental 
oxygen induced a substantial increase in hypoventilation as shown by an increased 
PETCO,. 
In the subjects suspected to have obstructive breathing during sleep, it appeared 
to be easy to assess apnoeas as well as hypopnoeas by means of P^COj recording. 
P E T C0 2 monitoring showed either cessation of the signal (apnoea) or an oscillatory 
signal simultaneous with but inverse to the Sa0 2 signal (hypopnoea). 
Measurement of Р
Е1СОг is preferable to measurement of the oro-nasal airflow, 
since the latter often misses hypoventilation and hypopnoeas (4, 10). Moreover, 
PETCO., is of complementary value to oximetry. Firstly, hypoventilation induced by 
supplemental oxygen can be established. Secondly, hypopnoeas which are accom­
panied by only small dips in Sa0 2 (<3%, which is within the instrumental error) are 
detected by simultaneous swings in P^CO^ Finally, PEfiOt recording is considerably 
more sensitive than measurement of thoracoabdominal movements since 36% of the 
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Figure 5.2 This nocturnal recording from a patient with daytime sleepiness shows oxygen 
desaturations with a concomitant cessation in the Р
гт
СО
г
 signal and - increased 
thoracic movements which indicates obstructive apnoeas. 
Rgure 5.3 This nocturnal recording from a patient with daytime sleepiness shows oxygen 
desaturations with concomitant elevations in the PgrCOj signal and increased thoracic 
movements which indicates obstructive hypopnoeas. 
hypoventilation episodes was not accompanied by any change in breathing move­
ments. In this study respiratory movements were recorded with just one inductive 
Plethysmograph. Perhaps two Plethysmographs would allow better interpretations, 
especially of paradoxical breathing. Yet, limitations in the detection of hypoventilation 
as such will still remain with the Plethysmograph (5-9). 
The disadvantage of transcutaneous PC02 monitoring compared to the measure­
ment of end-tidal РСО
г
 is the slow response (95% response time 1-2 min) to step 
changes of PaC02 (2, 5, 8, 11-13). Therefore short apnoeas and hypopnoeas will 
easily be missed when using the transcutaneous method (2, 8, 13). 
It is concluded that P^COj measurement is useful in the detection of hypoventila­
tion during sleep in COPD patients, with and without oxygen, as well as in recording 
apnoeas and hypopnoeas in patients with OSA. The method compares favourably to 
oro-nasal airflow recording and is of complementary value to oximetry and measure­
ment of breathing movements. 
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6.1. Abstract 
We have developed an automated system to log movement from overnight video 
recordings. Its value with respect to the determination of sleep times and movement 
arousals is evaluated in eighteen patients, considering the results of the conventional 
sleep analysis as the gold standard. This study shows that the video movement system 
identifies sleep times and movement arousals adequately enough to be a satisfactory 
substitute for conventional sleep recording in clinical practice. 
6.2. Introduction 
It is well known that there is a close relationship between body movements and sleep/ 
wake activity (1). Movement detectors, such as wrist actigraphs, define sleep times and 
prolonged arousals (more than 10 minutes) fairly accurately (2,3,4). Since we perform 
eight hour overnight video recordings on all patients referred to the sleep laboratory, 
we have developed an automated system to log body movements directly from the 
videoscreen. This totally non-invasive technique has proved to be useful in assessing 
sleep disturbance in children (5). 
In the current study the value of the video movement system is evaluated in adults 
with respect to sleep times and movement arousals. The results of the conventional 
sleep analysis are considered to be the gold standard. Moreover, the reproducibility of 
the video movement system is assessed, as is any difference between the results 
derived from the video tape played back in the fast forward mode and those derived 
from playback in real time mode. 
Furthermore, because it has been shown that there is a relationship between 
changes in transient EMG activity or bodymovements and EEG synchronisation/ 
desynchronisatbn (6, 7, 8), we wondered if absence or presence of movements (as 
detected with the video system) would coincide with EEG synchronisation/ désynchro-
nisât ion. 
6.3. Methods 
6.3.1. Patients 
Eighteen patients, aged 37 to 58, participated in this study. They were referred to the 
sleep laboratory for various sleep problems, or for daytime sleepiness. The reproduc-
ibility test was done in ten of the 18 patients, and the fast forward versus real time 
video replay comparison in eight patients. 
6.3.2. Techniques 
Conventional sleep staging with EEG, EOG and EMG was recorded with a four 
channel tape recorder (9000-MPA, Oxford Medical). The analysis was intially per-
formed automatically using standard criteria (9). Important areas were checked 
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manually (sleep onset, awakenings) In addition each recording was carefully analysed 
for the number of movement arousals of more than, and less than, 2 seconds duration. 
A movement arousal was defined as an increase in EMG on any channel, which was 
accompanied by a change in pattern on any additional channel (9) 
Eight hour video recordings were made using a low level light camera The video 
movement system is a device which quantifies movement in 12 second epochs from 
six photodiodes placed directly on the video monitor screen. This technique was 
described previously (5) Criteria were established to define sleep times and movement 
arousals (table 6 1) 
Table 6 1 Definitions of sleep times and movement arousal for the two compared 
methods 
Sleep onset 
(SO) 
Wake after 
sleep onset 
(WASO) 
Wake up time 
(W) 
Movemenl 
arousal 
(MA) 
Video movement method 
Beginning of a period of 10 mm 
without movements 
Begins with a penod of three se-
quential 12 seconds movement 
epochs 
Ends when no movement occurs 
for 5 mm 
Begins with a penod of 10 move-
ment-epochs or more in 10 mm, 
and subsequently thereafter, with 
no absence of movements for 
more than 5 mm 
Movement during sleep 
Ends when a epoch with no 
movement occurs 
Conventional sleep analysis (9) 
Beginning of a period of stage 1 
or below for 2 mm 
Begins with a penod staged as 
W 
Ends with the occurrence of 
stage 1 or below, for 2 mm 
Begins with a period staged as 
W for 2 mm and subsequently 
thereafter, with no lapses below 
stage 1 for more than 2 mm 
Increase m EMG on any chan-
nel which is accompanied by a 
change m pattern on any addi-
tional channel 
6.3 3. Protocol 
All patients slept in the sleep laboratory for one night EEG, EMG, EOG and video 
recordings were made at the same time The video movement method was initially 
used with the tape played back in the real time mode The tracings from the conven-
tional sleep staging channels and the video movement device were analysed blind from 
each other Sleep times and movement arousals detected by these two techniques 
were compared patient by patient, epoch by epoch 
The reproducibility of the video movement technique was tested by analysing the 
video tapes twice, with the photodiodes attached to the screen in different places over 
the sleeping subject 
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The difference between playing back the video tape in the fast forward mode (50 
minutes) or in real time was evaluated with the photodiodes stuck on the screen in the 
same place during both modes. 
The data were examined for statistical significance using the appropriate tests. 
6.4. Results 
6.4.1. Sleep times 
The mean total sleep time of the patient group was 394 minutes (range, 208-480). 
They all had periods of REM sleep. Thirteen of 18 patients appeared to have consider-
able sleep disturbance due to sleep apnoeas or nocturnal panic attacks. 
Figure 6.1.a shows the plot of the video movement system from a patient with 
severely disturbed sleep due to apnoeas. Figure 6.1.b shows the video movement plot 
of a normal subject. 
There was no significant difference between the sleep times measured with 
conventional sleep analysis and those measured with the video movement device 
(table 6.2). The largest error was an overestimation of the total sleep time by the video 
device of 24 minutes. 
Table 6.2 Sleep times, as defined by the video method, compared to those as docu-
mented by the conventional method. No significant differences. 
Mean SD of Range 
difference difference 
Sleep onset (min) - 0.9 
WASO(min) - 2.9 
Wake up time (min) + 0.7 
Total sleep time (min) + 4.0 
Total sleep time is the time between sleep onset and wake up time, minus the periods awake 
after sleep onset 
6.4.2. Movement arousals 
No movements occurred in the video-derived data that were not either logged as 
movement arousals or occurred whilst awake, as defined by conventional sleep 
staging. A total of 519 movement arousals in the 18 subjects, with a duration of at least 
2 seconds, were documented of which 427 (82%) were picked up by the video system. 
Figure 6.2 is a scatter plot showing that the number of movement arousals which were 
detected with the video method correlate very well with those documented by the 
conventional sleep stager (r - 0.99). The movement detector underestimated the 
5.5 
0.3 
2.2 
6.5 
-10 to +11 
-24 to +24 
- 2 to + 8 
-23 to +24 
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Figure 6.1 Eight-hour plot of movements against time, (a) A patient with sleep disturbance due 
to OSA emd (b) a normal person. Each horizontal block is 1 h with the start at the top 
left and the end at the bottom right. The height of the movement lines is only semi-
quantitative. 
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Figure 6.2 Correlation between movement arousals (>2s) documented by the conventional 
method and those detected by the video movement method. Regression equations; 
X-1.2 Y (SE 0.01) where X represents the actual number of movement arousals as 
documented by the conventinal sleep staging channels and Y represents the move­
ment arousals picked up by the video system. 
movement arousals, but with a fairly consistent percentage (table 6.3). The percentage 
missed did not vary with the actual number of arousals. Nor was there any difference 
in the percentage missed between patients with and without sleep disturbance. The 
real number of arousals (of at least 2 seconds by conventional sleep staging) could be 
predicted from the video derived data by multiplication by 1.2 (standard error 0.01). 
If all the movement arousals were taken into acount (both > or < 2 sec), a total of 
884 was documented of which 614 (70%) were picked up by the video movement 
system. The percentage missed was greater than for arousals of at least 2 seconds 
duration (table 6.3) because movement arousals of less than 2 seconds duration were 
missed more frequently. 
Tabel 6.3 Percentage of movement arousals, as documented by the conventional 
method, that are missed by the video method. 
Mean 
difference 
SD of 
difference 
Range 
Arousals > 2 sec 
% of actual number missed -17.6 
All arousals 
% of actual number missed -28.9 
5.1 
7.3 
-10 to - 2 5 
-15 to - 3 9 
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6.4.3. Reproducibility 
The total sleep time between the first and second analysis of the video tapes differed 
on average by 5 1 minutes, varying from -8 5 to 11 (table 6.4). The percentage of the 
12 seconds epochs registering movement was also calculated to provide a measure of 
the reproducablihty of the detection of movements A mean difference of 0 5% of 
epochs with movement (range -5 3 to 1 3) was found between the first and the second 
time 
6.4.4. Comparison between fast forward/ real time playback mode 
In the fast forward mode the total sleep time was on average underestimated by 4 6 
minutes (range -2 5 to 27)(table 6 5) None of the differences in sleep times or in time 
spent moving were statistically significant (paired t test). 
Table 6 4 Comparison of the data derived with the video movement system, used 
twice No significant differences 
Range 
Sleep onset (mm) 
WASO (mm) 
Wake up time (mm) 
Total sleep time (mm) 
% Time spent moving# 
Mean 
difference 
0Θ 
2 0 
0 2 
1 1 
- 0 5 
SD 
3 7 
5 0 
3 9 
5 6 
1 9 
6 
2 
6 
9 
5 
to 
to 
to 
to 
to 
+ 
+ 
+ 
+ 
+ 
9 
15 
10 
11 
1 
# Percentage of the 12-seconds epochs registering movement 
Table 6 5 Comparison of the results of the movement detector used m the fast 
forward play back mode and in real time No significant differences 
Mean SD Range 
difference 
Sleep onset (mm) 
WASO (mm) 
Wake up time (mm) 
Total sleep time (mm) 
% Time spent moving# 
1 5 
- 4 8 
- 1 0 
4 6 
- 0 5 
3 6 
109 
5 6 
123 
1 0 
5 
27 
14 
3 
• 3 
to 
to 
to 
to 
to 
+ 7 
+ 3 
+ 4 
+ 27 
0 
# Percentage of the 12-seconds epochs registering movement 
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6.4.5. Sleep staging 
In the normal subjects and in the patients with moderate sleep apnea, absence of 
movement arousals as detected with the video technique was associated with EEG 
synchronisation and descent into slow wave sleep on the conventional sleep staging 
channels; and presence of video movements with EEG desynchronisation and arousal. 
In the patients with severe sleep apnoea (> 15 per hour) we saw various different 
patterns which did not fit the no movement/ EEG synchronisation and movement/ EEG 
desynchronisation concept. The video system did not pick up any body movements 
during most of the undisturbed REM episodes. 
6.5. Discussion 
The video movement detector has proved to be a satisfactory method to define sleep/ 
wake times for clinical purposes. It is useful in sleep studies without full EEG, EOG, 
EMG recording, where a negative test, showing no breathing disorders, requires 
conformation that the subject did in fact sleep. A video recording is of course non 
invasive and can be made even in the patients' home (5). It is cheaper than the 
conventional sleep staging; the cost of the movement detector parts is £100. 
The movement detector has provided a good impression of movement arousals of 
at least 2 seconds. The actual number of arousals (as would be documented by the 
conventional sleep analysis) could be calculated quite precisely from the results of 
the video movement detector. The advantage of the video movement method against 
the conventional method is that the movement detector counts arousals automati-
cally. Even using the automated analysis of the EEG, EOG and EMG signals short 
arousals will be missed (Oxford Medical). Movement arousals of a duration less than 
half the staging epoch have to be added and scored manually. This is very time 
consuming. 
Furthermore the video movement technique was reproducable enough to be reliable 
in practice. 
Initially we had thought that there might be a difference in data derived from the 
video tape played back in the fast forward mode compared to the real time mode, due 
to screen flicker or the possibility of missing very fast movements. There appeared to 
be no significant difference in sleep times or movement arousals. Therefore we 
conclude that the video movement detector can be used in the fast forward playback 
mode. This takes fifty minutes, which is a considerable time saving in comparison with 
the eight hour real time mode. 
The video movement derived synchronisation/ desynchronisation pattern in our 
normals and moderate sleep apnoea patients (< 15 per hour) corresponded with the 
results of Schulz et al, who studied only normal subjects (7, 8). Our data indicate that 
in patients with severe sleep apnoea different synchronisation/ desynchronisation 
patterns may occur. Most of the REM episodes were not accompanied by movements 
on the video screen. The results of other studies with respect to the occurrence of 
movements during REM sleep, vary. Some investigators did not find many movements 
during REM sleep either (10, 11), whereas others did (6, 7, 8, 12). Presumably, this 
discrepancy can be explained by the difference in method and sensitivity used to 
73 
measure movements. Pilcher et al measured changes in transient EMG activity, which 
is far more sensitive than our detection of movements (8). 
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7.1. Abstract 
The selective attention of 39 patients with chronic obstructive pulmonary disease (COPD) 
was measured by the Bourdon-Vos test and compared with the attention performance 
of 38 healthy controls of the same age range. The correlation between the attention of 
the COPD patients and day- and nighttime parameters was determined. Furthermore, 
in 44 other COPD patients with daytime hypoxaemia, the effect of one-night oxygen 
supplementation and of a seven-day treatment with the respiratory stimulants Chlormadi­
none acetate or acetazolamide on attention performance, was studied. 
The results showed that the attention performance of COPD patients was lower 
than that of the controls. Significant correlations were found between the mean line 
time (attention parameter) and the following parameters: age (r=0.33), vital capacity 
(Г--0.35), hypercapnic ventilatory response (r--0.43), daytime Sa02 (Г--0.33), daytime 
Pa02 (r=-.28), daytime PaC02 (r-0.31), mean nocturnal Sa02 (r—0.33), lowest 
nocturnal Sa02 (r--0.33) and the standard deviation of the mean nocturnal Sa02 (r-0.42). Multiple linear regression analysis showed that, apart from age, only the nadir 
of the nocturnal Sa02 contributed to the prediction of the attention. 
No clinically important short-term effect of oxygen or respiratory stimulating therapy 
on the attention performance could be assessed. 
Keywords; Chronic obstructive pulmonary disease, cognitive function, attention, 
hypoxaemia 
7.2. Introduction 
Patients with chronic obstructive pulmonary disease (COPD) have a lower neuropsy­
chological performance than healthy controls (1-5). Most of their neuropsychological 
functions correlate inversely with the daytime arterial oxygen tension (Pa02)(2-5). 
Moreover, the impaired mental function appears to be partly reversible with long-term 
oxygen therapy (1, 6, 7). Results of studies about the short-term effect of oxygen 
supplementation on cognitive function in other (non-COPD) patients are inconsistent 
(8-10). 
The correlation between the neuropsychological function and the Pa02 was found 
to be low (r=0.2 (2, 3, 5), r= 0.3 (4). There must be other factors, therefore, that 
contribute to the impaired cognitive function in COPD patients. Parameters of pulmon­
ary function appeared not to correlate significantly with the cognitive performance (2, 
4). The extra hypoxaemia that occurs in COPD patients during sleep may be involved, 
but this has not been investigated (2,11). Yet in heavy snorers and in patients with the 
obstructive sleep apnoea syndrome, it has been indicated that nocturnal hypoxaemia 
is related to the cognitive performance (12-17). Another f actor that has been suggested 
to affect the cognitive function is the presence of hypercapnia, although significant 
correlations have not been assessed (2, 5, 18, 19). Furthermore, the effect that 
therapeutic intervention resulting in a decrease of the arterial carbon dioxide tension 
(PaC02) has on cognitive function, has not been studied yet. 
In the current study the selective attention or mental concentration as a parameter 
of cognitive function is tested, since it is probably one of the first cognitive abilities 
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which is affected by hypoxaemia (20). The usefullness of the Bourdon-Vos test in this 
respect, was investigated (21). Since it is not feasible to perform a whole battery of 
neuropsychological tests in a pulmonary clinic, this short test (± 10 min) may be useful 
in many practical clinical situations. 
The aims of this study were the following; firstly to determine if COPD patients 
indeed have an impaired attention as compared to healthy controls of the same age 
range. Secondly, to determine the correlation between the attention performance of 
COPD patients and age, body mass index, daytime blood gas values, pulmonary 
function and nighttime oxygenation. Finally, the effect of one-night oxygen 
supplementation on attention performance in COPD patients with daytime hypoxaemia 
is tested, as well as the effect of a seven-day treatment with respiratory stimulants 
(Chlormadinone acetate and acetazolamide) which decrease the arterial carbon dioxide 
tension. 
7.3. Methods 
7.3.1. Patients 
In this study two different groups of COPD patients participated. The first group 
consisted of 39 COPD patients (31 men, 8 women), with an age between 55 and 77 
years. The second group of 44 COPD patients included only patients with daytime 
hypoxaemia, defined as a Pa02 value below 8.5 kPa. All COPD patients were in a 
stable clinical condition and received optimal bronchodilator treatment. Their FEV, 
(forced expiratory volume in one second) value had to be less than 65% of the 
predicted value (22). The characteristics of the COPD patients are shown in table 7.1. 
Table 7.1 Charisterics of two groups of COPD patients 
Number of patients 
Body mass index 
FEV, (% predicted) 
IVC (% predicted) 
TLC (% predicted) 
FRC (% predicted) 
RV (% predicted) 
HCVR (l/min/kPa) 
РаО
г
 daytime (kPa) 
PaCOj daytime (kPa) 
Mean nocturnal Sa0 2 (%) 
S.D. of mean noct. Sa0 2 
Lowest nocturnal Sa0 2 (%) 
1st group 
39 
23 (4) 
33 (10) 
81 (17) 
99 (23) 
131 (36) 
144 (45) 
3.7 (4) 
8.9(1.4) 
5.7(1.0) 
88.5 (5) 
2.6 (2) 
78.3 (10 
2nd group 
44 
24 (4) 
30 (10) 
80 (14) 
100 (18) 
134 (30) 
154 (46) 
2.4 (2) 
7.5(1.0)* 
6.4(1.2)* 
85.1 (10)* 
3.4 (2) * 
74.0 (15)* 
* ρ < 0.05 
HCVR: Hypercapnic ventilatory response 
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Also, thirty-eight healthy subjects (16 men, 22 women) were randomly recruited from 
a general practice. Inclusion criterion was an age between 55 and 77 years. The mean 
age (±SD) of this group was 64.8 (±5) years. 
The healthy subjects were studied at home and the COPD patients in hospital, all 
at 10.00 a.m. 
All persons with obvious conditions that would interfere with the results, such as 
psychiatric disorders, alcoholism, cerebral vascular disease, use of benzodiazepines, 
poor sight or shaking hands were excluded. 
7.3.2. Techniques 
Selective attention was measured by the Bourdon-Vos test (21)(fig 7.1). This is a 
modified version of the traditional Bourdon test (23, 24). The test consists of 33 lines 
each with 24 configurations of 3 to 5 dots. Patients were instructed to mark all con-
figurations of four dots as quickly as possible. The omissions, as a parameter of 
accuracy, and the time of each line, which indicated speed, were recorded. Every 
person performed the test at least twice on separate days. The results of the first and 
the second test were compared in view of the expected practice effect (21). Drinking 
coffee was forbidden within three hours before performing the test. 
Figure 7.1 Example of five lines of the Bourdon-Vos test 
In all patients with COPD the pulmonary function, including the hypercapnic ventilatory 
response, was measured and arterial blood gas samples were taken. Oxygen satura-
tion was recorded from 10.00 p.m. until 6.00 a.m. by a pulse-oximeter (Oxyshuttle, 
SensorMedics). The saturation data of the whole night were stored, digitized and 
analysed by a computer (Apple Me) to provide the mean and the lowest saturation of 
each night as well as the standard deviation of the mean saturation. 
7.3.3. Protocol (fig 7.2) 
The attention performance of the group of 39 COPD patients was compared with the 
performance of the healthy subjects with the same age range. Because of the different 
gender composition of the COPD and the control group, the difference in attention 
performance between men and women in both groups was determined. 
The data of the group of 39 COPD patients were used to determine the correlation 
between attention performance and age, body mass index, daytime blood gas values, 
pulmonary function and nighttime oxygenation. 
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Figure 7.2 Protocol. Test 1 is a training test 
The effect on attention performance of therapeutic interventions (0 2 l CMA, ACET), 
aiming at an improvement of the arterial P02 or РСОг, was studied in the group of 44 
COPD patients with daytime hypoxaemia. Thirty-one of these patients recieved 
nocturnal oxygen supplementation and were tested the next day while breathing room 
air. The other 13 patients received day- and nighttime oxygen treatment so they 
performed the third attention test while breathing supplemental oxygen. Next, eleven 
of the 44 hypoxaemic COPD patients were treated with 25 mg of Chlormadinone 
acetate twice a day for one week. Nine hypoxaemic patients received 250 mg of 
acetazolamide two times a day during one week. The other eleven patients performed 
another test while breathing room air after one week in order to determine the long-
term reproducibility of the test. 
7.3.4. Statistical analysis 
Statistical analysis was performed using the Wilcoxon test. Correlations were estab­
lished by means of the Spearman rank test. Multiple linear regression was used to 
indicate partial correlations, ρ values of 0.05 or less were considered to be significant. 
7.4. Results 
7.4.1. Practice effect 
The line times of the second attention test were significantly shorter than those of the 
first test, in the healthy controls as well as in the patients with COPD. The mean line 
time of the control group decreased from 13.6 (3) seconds to 12.6 (2) seconds. In the 
COPD group the mean line time changed from 15.0 (3) to 14.1 (3) seconds. In 
addition, in the patients with COPD significantly fewer omissions were recorded in the 
second test than in the first test (10 and 14 respectively). 
No significant difference was found between the results of the second and the third 
test. 
7.4.2. Comparison of patients with COPD and healthy controls 
The results of the attention test of the first group of 39 patients with COPD and the 
healthy controls of the same age range are shown in table 7.2. The control group had 
significantly shorter line times than the COPD patients. No significant difference in 
attention performance between men and women was assessed in the COPD group or 
in the control group. 
7.4.3. Correlation of the attention with patient characteristics 
Table 7.3 shows the correlation between the attention parameters and characteristics 
of the group of 39 COPD patients. The mean line time was significantly correlated with 
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age, inspiratory vital capacity, hypercapnic ventilatory response, daytime Sa02, daytime 
Pa02, daytime PaC02) mean nocturnal 8аОг, lowest nocturnal Sa02 and with the 
standard deviation of the mean nocturnal Sa02. The number of omissions was 
significantly correlated with the awake Sa02. Multiple linear regression analysis 
indicated the contribution of the above-mentioned parameters to the prediction of the 
mean line time (LT). Age (A)(11%) and the lowest nocturnal Sa02 (Sa02 low)(9%) 
contributed significantly to the total variance of 20%. The regression equation was: 
LT = 10.6 + 0.16 A - 0.09 Sa02 low. 
Table 7.2 Results of the attention test of 39 COPD patients compared to those of 38 
controls of the same age range (SD). 
COPD Controls 
Overall mean linetime (s) 
Mean line time 0-11 (s) 
Mean linetime 11-22 (s) 
Mean line time 22-33 (s) 
Total omissions 
14.1 (3) 
14.4 (3) 
13.9 (3) 
14.0 (3) 
10 (0-57) 
12.6 (2) 
12.7 (2) 
12.4 (2) 
12.7 (2) 
7 (0-28) 
* ρ < 0.05 
Table 7.3 Correlation coefficients between attention and daytime/nighttime para­
meters. 
Age 
IVC (% predicted) 
HCVR (l/min/kPa)# 
Sa0 2 awake (%) 
Pa0 2 awake (kPa) 
PaCOj awake (kPa) 
Mean nocturnal Sa0 2 (%) 
S.D. of mean noct. Sa0 2 
Lowest nocturnal Sa0 2 (%) 
Mean line time (s) 
0.33 (*) 
- 0 . 3 5 * 
- 0 . 4 3 * 
- 0 . 3 3 * 
-0.28 (*) 
0.31 (*) 
-0.33 * 
0.43 * 
-0.33 * 
Omissions 
0.28 
0.13 
0.01 
- 0 . 3 3 * 
- 0 . 5 9 
0.15 
- 0 . 1 9 
0.06 
0.02 
* ρ < 0.05 
Π 0.01 < ρ < 0.05 
HCVR: Hypercapnic ventilatory response 
No significant correlations were found with body mass index, FEV,, TLC, RV and FRC 
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Table 7.4 Results of the 44 hypoxaemic COPD patients 
Room air Nighttime Room air 
(N-31) О
г
 (N-13) 
Mean time lines 0-33 (s) 
Mean time lines 0-11 (s) 
Mean time lines 11 -22 (s) 
Mean time lines 22-33 (s) 
Total omissions 
13.5 (3) 
13.7 (4) 
13.3 (3) 
13.4 (3) 
12 (0-44) 
13.3 (3) 
13.6 (3) 
13.1 (3) 
13.2 (3) 
12 (0-43) 
15.7 (4) 
15.8 (4) 
15.5 (3) 
15.7 (4) 
12 (2-57) 
Night- and Before With Before With 
daytime 0 2 (N-11) CMA (N-9) ACET 
15.3(4) 
15.7 (4) 
15.0(4) 
15.2(5) 
11 (1-28) 
13.4 (3) 
13.4 (2) 
13.2 (3) 
13.6 (3) 
14(0-44) 
12.9 (3) 
13.1 (3) 
13.2 (3) 
12.7 (4)* 
10 (0-39) 
13.6 (4) 
14.0 (4) 
13.5 (4) 
13.6 (3) 
12 (0-22) 
14.2 (4) 
14.5 (4) 
13.7 (4) 
14.1 (5) 
10 (0-25) 
* ρ < 0.05 comparison with room air night 
7.4.4. Short-term effect of oxygen supplementation and respiratory 
stimulants 
The mean daytime РаО
г
 of the hypoxaemic patients with COPD increased during 
oxygen supplementation from 7.4 up to 9.9 kPa. The mean daytime PaC02 increased 
from 6.4 to 7.0 kPa. Table 7.4 shows the results of the patients tested with and without 
oxygen supplementation. No significant changes in attention performance were seen 
during oxygen therapy. 
After a one-week treatment with Chlormadinone acetate the mean daytime Pa02 
increased from 7.2 to 7.8 kPa and the PaC02 decreased from 6.5 to 5.8 kPa. Acetazo-
lamide increased the PaOz from 7.5 to 9.4 kPa, and decreased the PaCO-, from 6.4 to 
5.9 kPa. The lowest nocturnal Sa02 did not change during Chlormadinone acetate 
treatment and during acetazolamide an increase from 70% to 77% was found. The 
results of the attention test are shown in table 4. During Chlormadinone acetate therapy 
a positive trend in attention performance was seen. However, this was only significant 
in the mean time of the last eleven lines. 
7.5. Discussion 
This study showed that patients with COPD had an impaired attention performance 
compared to healthy controls of the same age. This finding is consistent with those of 
others (1-5). The COPD group and the control group were not matched for education, 
since no significant influence is known between education and the performance of the 
Bourdon-Vos test (22). It was assumed that the gender difference between the COPD 
and the control group had no effect on the results, since no difference could be 
assessed in attention performance between men and women. 
The attention of the COPD patients was significantly inversely related to oxygen­
ation. In other words, hypoxaemia seemed to have an adverse effect on the brain 
function. This was also shown in healthy subjects at high altitude (20, 25, 26). This is 
reasonable since oxygenation is essential for the neural biosynthetic processes (20, 
27, 28, 29). Only a low correlation coefficient (r=-0.3) of the attention with daytime 
oxygenation was found in this study and in those of others (2-4). The current study 
also assessed a correlation with the nighttime oxygenation. A similar correlation had 
been shown in heavy snorers and in patients with obstructive sleep apnoeas (13, 14, 
17). Moreover, linear regression analysis in this study showed that besides age, only 
the lowest nocturnal Sa02 contributed to the prediction of the attention performance. 
Perhaps the extra hypoxaemia itself is responsible for the deterioration in attention, or 
the arousals caused by the nocturnal hypoxaemia play a role. The latter explanation is 
less likely since no significant relationship could be found between arousals and 
cognitive function in studies with patients with the sleep apnoea syndrome (13, 14). 
Since hypoxaemia adversely influences attention, one would expect some benefit 
of reversal of the hypoxia. It has been shown that short-term oxygen augmented 
oxygen-dependent enzymes necessary for the stimulation of neurotransmitters (20). 
Nevertheless, in our group of 41 hypoxaemic patients no effect on the attention 
performance could be assessed after treatment with oxygen for one night, neither 
when they were tested in hypoxaemic, nor in oxygenated condition. This was consist-
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ent with results of others in non-COPD patients (9, 10). There was not a significant 
effect of acetazolamide therapy on attention either. In the Chlormadinone acetate group 
a tendency of improvement in attention could be indicated. This positive effect cannot 
be explained by the practice effect since this study has shown that only the first time 
is affected but that second and third performances are reproducible. It is not likely 
either that the correction of the hypercapnia was the reason for the trend of improved 
attention performance, since the acetazolamide group did not show this partial 
improvement. 
The mean line times during room air of the group of 39 COPD patients and those 
of the 31 and 13 hypoxaemic patients differed slightly (table 7.2, table 7.4). The reason 
for this difference was probably the different age of the groups which was 65.9, 63.9 
and 66.7 years respectively. 
All studied parameters together could only account for 20% of the variance in 
attention. Concomitant diseases as heart failure and atherosclerosis might be of 
influence as well as depression and fatigue which is often shown in patients with 
chronic diseases (30). Or perhaps sleep fragmentation due to nocturnal coughing and 
dyspnoea played a role. 
It is concluded the attention performance of COPD patients is lower than that of the 
controls. Multiple linear regression analysis showed that, apart from age, only the nadir 
of the nocturnal Sa02 contributed to the prediction of the attention in patients with 
COPD. Neither one-night oxygen suppletion nor one-week Chlormadinone acetate or 
acetazolamide improved the attention performance in hypoxaemic patients with COPD. 
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8.1. Abstract 
The effects of clormadinone acetate (CMA), acetazolamide (ACET) and oxygen on 
awake and asleep blood gas values were studied in fifty-three hypoxaemic patients 
with chronic obstructive pulmonary disease (COPD). The trial was randomised, double-
blind and placebo-controlled. On the first two consecutive nights all patients received 
either room air or oxygen, via a nasal cannula, in random order. Next they either 
received CMA (25 mg), ACET (250mg) or placebo twice a day, all in Identical capsules. 
On the third study night, after one-week drug treatment, the patients were tested 
receiving room air. 
CMA and ACET therapy decreased daytime PaC02 (0.7 and 0.5 kPa respectively) 
and nighttime PETCO,, (0.5 and 0.3 kPa), whereas supplemental oxygen caused 
increased C0 2 retention during the day and night (0.6 and 0.3 kPa). Daytime Pa02 
increased during ACET (1.9 kPa) and oxygen (2.5 kPa) to the same extent. Asleep 
oxygen saturation improved most with oxygen supplementation (7%), though ACET 
also achieved a significant improvement (4%). CMA administration had virtually no 
effect on awake and asleep hypoxaemia on a group level. ACET therapy improved 
significantly the subjective sleep quality and during oxygen supplementation a benefi-
cial trend was observed. On CMA, minute ventilation increased in association with an 
augmentation of the hypercapnic ventilatory response. ACET treatment increased both 
the hypercapnic as well as hypoxic ventilatory response. 
Sixteen per cent of the patients treated with CMA and 53% of those treated with 
ACET attained an acceptable level of day- and nighttime oxygenation and carbon 
dioxide tension. 
It was concluded that in the group of patients with COPD studied, the effects of 
ACET treatment on gas exchange were favourable to those of CMA. Oxygen therapy 
improved oxygenation slightly more than ACET, but aggravated the C02 retention. 
Individual patients may benefit from CMA or ACET therapy as an alternative - or 
perhaps in addition - to oxygen supplementation. 
8.2. Introduction 
Hypoxaemic patients with chronic obstructive pulmonary disease (COPD) may develop 
more profound oxygen desaturations during sleep (1). Treatment of hypoxaemia is 
beneficial since hypoxaemia leads to pulmonary hypertension, cor pulmonale, second-
ary polycythaemia, and cardiac arrhythmias (2-6). Indeed it has been shown that long-
term oxygen supplementation for at least 18 h/day can increase life expectancy in 
these patients (8, 9). 
Drugs that stimulate ventilation may ameliorate hypoxaemia as well as carbon 
dioxide retention in certain patients with COPD (9-17) and may thus provide a possibly 
alternative, or additional treatment to oxygen supplementation. 
Medroxyprogesterone and Chlormadinone acetate (CMA) raise arterial oxygen 
tension and reduce carbon dioxide tension during wakefulness by central stimulating 
effects (10-18). The effects on hypoxaemia during sleep were beneficial (10-12,16) or 
absent (13,17). Not much is known about the effect of progesterone on carbon dioxide 
tension during sleep (11, 12). 
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Another respiratory stimulant is acetazolamide (ACET). It is a powerful carbonic 
anhydrase inhibitor which increases ventilation, partly by raising tissue PC02, and 
partly by inducing a metabolic acidosis, possibly acting on both the peripheral and the 
central chemoreceptors (19-21). It diminishes nocturnal hypoxaemia and periodic 
breathing at high altitude (22,23). ACET has been shown to improve blood gas values 
during the day and at night, in a few patients with COPD (9, 12). 
The aim of the current study was to determine if CMA and ACET have a clinical 
value in the treatment of hypoxia and hypercapnia and to compare the results with 
those derived during oxygen therapy. Therefore the effects of CMA, ACET and oxygen 
on blood gas values during wakefulness and sleep were studied in a group of hypo-
xaemic patients with COPD. Furthermore, the effects on subjective sleep quality, on 
patients' subjective feeling of wellbeing and on control of breathing were measured. 
8.3. Methods 
8.3.1. Patients 
Fifty-three outpatients with chronic obstructive pulmonary disease, as defined by the 
American Thoracic Society, participated in this study (24). Inclusion criteria were: FEV, 
value less than 65% of the predicted value (25), and daytime Pa02 values of 8.5 kPa 
or less. At the time of the study all patients had been in a stable clinical condition for 
at least four weeks and received optimal bronchodilator treatment. Exclusion criteria 
were: thromboembolic events in the past, and factors suggesting possible obstructive 
sleep apnoea, such as complaints of excessive daytime sleepiness or anomalies of the 
oro-pharyngeal area. All medication of the patients was continued and remained 
unchanged during the study period. Patients who were already treated with supple­
mental oxygen at home were allowed to continue this during the one week's pharmaco­
logical treatment. The characteristics of the patients are shown in table 8.1. 
8.3.2. Techniques 
8.3.2.1. Daytime 
The hypercapnic ventilatory response was assessed by the steady-state method (26, 
27). The patient was connected to a closed spirometrie circuit via a mouthpiece. The 
end-tidal PC02 level could be increased by adjusting a three-way valve, partially short-
circuiting the СО
г
 absorber in the inspiratory limb of the circuit. Two different levels of 
PETC02 were studied. The oxygen saturation level was maintained at the initial resting 
level by adding oxygen to the system. 
The hypoxic ventilatory response was performed by inducing progressive isocapnic 
hypoxia (28). PETC02 was maintained at the initial resting level. All patients started the 
test at a Sa02 level of 90-93%. The hypoxic ventilatory response was stopped when 
the Sa02 reached 80%. 
Furthermore, the capability of the ventilatory pump of the patients to lower their 
carbon dioxide tension was determined by asking them to hyperventilate. 
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Table 8.1 Day- and nighttime charactenstics of the patients (mean value (SD)) 
Sex 
Age (yrs) 
FEV, (% predicted) 
IVC (% predicted) 
TLC (% predicted) 
FRC (% predicted 
RV (% predicted) 
Pa0 2 daytime (kPa) 
pH 
PaCOj daytime (kPa) 
Base excess 
HCVR (l/mm/kPa) 
HVR (l/mm/kPa) 
VE (l/mm) 
VT(I) 
f 
Body mass index 
Neck circumference (cm) 
Whole 
group 
Э9М 
65 
30 
75 
101 
132 
151 
7 4 
7 42 
6 4 
5 9 
2 4 
0 2 0 
9 7 
0 57 
19 
24 
39 6 
,14F 
(9) 
(10) 
(14) 
(18) 
(30) 
(46) 
(10) 
(0 03) 
(12) 
(4 2) 
(17) 
(015) 
(2 5) 
(0 2) 
(5) 
(4) 
(3 3) 
Baseline Sa02 night awake (%)87 8 (7 4) 
Mean Sa0 2 night (%) 
S D of mean Sa0 2 night 
Lowest Sa0 2 night (%) 
Fall in SaO, (%) 
Fall in Pa02 (kPa) calculated 
4% dips 
Baseline PETCOJ awake (kPa) 
Baseline PETCOJ, asleep (kPa) 
Highest PETCOJ asleep (kPa) 
Rise in PETCO., (kPa) 
Desaturation time (mm) 
Total sleep time (hrs) 
Movement arousals (per hour; 
84 4 
3 4 
72 
16 
2 5 
17 
5 2 
5 4 
6 7 
1 5 
47 
5 1 
7 
(9 5) 
(16) 
(15) 
(10) 
(1) 
(11) 
(0 9) 
(10) 
(13) 
(0 9) 
(63) 
(17) 
(3) 
CMA 
group 
14M, 
64 
31 
78 
99 
129 
142 
7 2 
7 42 
6 5 
6 2 
2 3 
0 20 
9 6 
0 55 
19 
23 
39 2 
85 6 
821 
3 6 
71 
17 
2 3 
17 
5 0 
5 2 
6 6 
1 4 
41 
5 4 
7 
4F 
(9) 
(11) 
(14) 
(14) 
(26) 
(38) 
(11) 
(0 03) 
(13) 
(5 3) 
(15) 
(0 20) 
(2 7) 
(0 2) 
(5) 
(4) 
(2 6) 
(9 1) 
(11) 
(2 0) 
(15) 
(9) 
(1) 
(9) 
(0 7) 
(10) 
(14) 
(10) 
(55) 
(16) 
(4) 
ACET 
group 
11M, 
64 
31 
75 
100 
131 
146 
7 5 
7 42 
6 4 
6 6 
2 7 
0 22 
105 
0 61 
19 
23 
39 5 
88 2 
84 8 
3 4 
70 
19 
2 7 
19 
5 2 
5 3 
6 7 
1 6 
62 
4 6 
7 
6F 
(6) 
(9) 
(14) 
(18) 
(31) 
(41) 
(11) 
(0 03) 
(13) 
(4 6) 
(2 4) 
(0 16) 
(2 7) 
(0 2) 
(5) 
(4) 
(4 0) 
(8 5) 
(11) 
(16) 
(22) 
(15) 
(1) 
(16) 
(0 7) 
(0 9) 
(11) 
(0 9) 
(89) 
(17) 
(3) 
Placebo 
group 
14M, 
65 
29 
70 
103 
135 
163 
7 5 
7 41 
6 3 
4 8 
2 2 
019 
9 4 
0 56 
18 
25 
4 0 1 
69 6 
86 4 
3 1 
75 
16 
2 5 
16 
5 4 
5 7 
6 9 
1 5 
41 
5 3 
7 
4F 
(9) 
(9) 
(10) 
(21) 
(33) 
(57) 
(0 8) 
(0 04) 
(0 8) 
(2 0) 
(12) 
(010) 
(2 1) 
(0 2) 
(4) 
(5) 
(3 2) 
(2 7) 
(4 3) 
(1 1) 
(6) 
(10) 
(1) 
(5) 
(12) 
(13) 
(13) 
(0 5) 
(39) 
(16) 
(3) 
HCVR hypercapmc ventilatory response 
HVR hypoxic ventilatory response 
VE minute ventilation 
VT tidal volume 
f breathing frequency 
Fall in Sa0 2 baseline Sa0 2 awake minus lowest Sa0 2 asleep 
Fall in Pa02 calculated from Sa0 2 with Hill equation 
Rise in РвтСОг highest Р^СОг asleep minus baseline PETCOJ awake (see table 8 5) 
None of the characteristcs is significantly different between the CMA-, the ACET- and the 
placebo-group 
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8.3.2.2. Nighttime 
The oxygen saturation was measured by a pulse-oximeter (Oxyshuttle, SensorMedics). 
The saturation data of the whole night were stored, digitized and analysed by a 
computer (Apple Me) to provide the mean and the lowest saturation of each night as 
well as the standard deviation of the mean saturation. Nocturnal Pa02 was calculated 
from the measured Sa02 values (Hill-equation). The awake and asleep baseline Sa02 
was defined as the mean saturation 15 minutes before falling asleep and while 
sleeping, respectively. Desaturation was defined as a decrease in oxygen saturation 
from the asleep baseline Sa02 of more than 4%. The total desaturation time was 
calculated. 
The thoracoabdominal movement was assessed by respiratory inductance plethys-
mography (Vitalog or Respitrace). 
The PETC02 was determined by introducing a cannula through the nose into the 
naso-pharyngeal cavity. An air sample was taken via a perma-pure drying tube 
connected to a sampling capnograph (Mijnhart capnolyser). The PETCOJ signal was 
analysed together with oxygen desatu rations. No PEJCOJ signal and thus no air 
movement for at least 10 seconds, was considered to indicate apnoea. A desaturating 
episode accompanied by an increased PETC02 for at least 10 seconds was considered 
to indicate hypoventilation. Hence the PEJCOJ signal provided information about the 
presence of nasal and oral airflow. In addition, increases in PETCOJ could be used as 
an indication of hypoventilation. Baseline PETCOJ awake and asleep was defined as the 
mean PETCO,, value 15 minutes before falling asleep and while sleeping respectively. 
PETC02 was not considered representative of arterial PC02. 
An electrooculogram was performed with surface electrodes to indicate REM sleep. 
Overnight videorecordings were made in 26 randomly selected patients during the 
control night and during the night with drug treatment. Sleep and sleep disturbance 
were determined by an automated system that logged body movements from the video 
monitor (29). A computer program was developed to determine total sleeptime and 
movement arousals. 
8.3.3. Protocol (fig 8.1) 
Prior to the study, pulmonary function tests were performed and an arterial blood gas 
sample was taken. The naso- and oro-pharyngeal area was examined and the neck 
circumference was measured. 
All patients were studied during three nights; two consecutive nights during which 
they received either room air or oxygen in a random order. On the third night, after one 
week of drug administration, the patients were studied receiving room air. Room air as 
well as oxygen was administered via a nasal cannula at 1 I/min, in a single-blind way. 
The part of the study with the pharmacological respiratory stimulants was randomised, 
double-blind and placebo-controlled. After the first two study nights the patients orally 
took either CM A (25 mg), ACET (250 mg) or placebo, all in identical capsules (8 am 
and 8 pm) for a period of one week. The patients were randomised within each of the 
four subgroups, defined according to FEV, value (above or below 35% of the predicted 
value) and daytime Pa02 (above or below 7.5 kPa). 
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Figure 8.1 Protocol; day number 0, and test day/night number 1, 2 and 3; fourteen to 
fourty days later 
# # 
CMA, ACET or placebo 
0 1 2 3 
air on oxygen air 
random order 
0: Pulmonary function, arterial blood sample, patient characteristics 
1, 2, 3: Oximetry, Р
е т
СО
г
, thoracoabdominal movement, EOG, videorecording during the night 
*: Arterial blood sample, sleep questionnaire 
#: Hypercapnic and hypoxic ventilatory response, plasma testosterone, sodium, potassium, 
kreatinine and white blood cells 
After each study night arterial blood gas samples were taken at 10.00 am, after 15 
minutes of rest. These blood gas values were compared to the sample that was taken 
two to four weeks before the start of the study, in order to confirm the stability of the 
disease. Furthermore, after each study night the patients answered the St. Mary's 
Hospital sleep questionnaire concerning subjective sleep quality (30). After the first 
night and after one week of "drug treatment", plasma-testosterone levels, white blood 
cells, sodium, potassium and kreatinine concentration were measured. On these two 
days the ventilatory responses to hypercapnia and hypoxia were also measured. 
Informed consent was obtained from all patients, and the study was approved by 
the Hospital Ethics Committee. 
8.3.4. Statistical analysis 
Statistical analysis for paired comparisons was performed using the signed rank test, 
except for differences on an ordinal scale: in such cases the sign test was used. The 
Kruskal-Wallis test was used to determine possible statistically significant differences 
between the three groups. Relations between variables were evaluated by Spearman 
rank's correlation, ρ values of 0.05 or less were considered to be significant. 
8.4. Results 
8.4.1. Daytime laboratory measurements 
The effects of CMA, ACET, placebo and oxygen therapy on daytime blood gas values 
are shown in table 8.2 and figure 8.2. Daytime hypoxaemia improved with ACET (1.9 
kPa) and О
г
 therapy (2.5 kPa) to the same extent, whereas CMA increased РаО
г
 just 
slightly (0.6 kPa), and not significantly different from placebo (0.4 kPa). Arterial PC02 
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significantly decreased during CMA and ACET therapy, by an average of 0.7 and 0.5 
kPa respectively. During supplemental oxygen РаСО
г
 increased by 0.6 kPa. 
Table 8.2 Effects of CMA, ACET and 0 2 on daytime blood gas values 
Differences (SD); results after minus before "treatment" 
CMA ACET Placebo О
г 
Pa0 2 daytime (kPa) 
pH 
PaC02 daytime (kPa) 
BE 
0.6 (0.9)° 
0.01 (0.03)" 
-0.7 (0.6)°" 
-2.0 (1.8)°" 
1.9 (I.O)""0 
-0.07 (О.ОЗ)8"0 
-0.5 (0.6)°" 
-6.6 (3.3)°"° 
0.5 (0.5)° 
0.01 (0.02) 
0.3 (0.4)° 
0.0 (0.8) 
2.4 {1.02)°be 
0.02 (0.02)°* 
0.6 (0.5)"° 
0.7 (1.5)°"* 
ρ < 0.05; comparison with data before therapy 
ρ < 0.05; comparison to placebo 
ρ < 0.05; comparison ACET to CMA 
ρ < 0.05; comparison 0 2 to ACET 
ρ < 0.05; comparison 0 2 to CMA 
Δ 
Ρθθ2 
(kPa) 3 
1 
О 
Δ -1 
РаСОг 
(кРа) 
-2 
0 
И 
4 
СП СМА • ρ < 0.05 
ΖΖΖ ACET 
Figure 8.2 The changes (± SD) in arterial daytime oxygen and carbon dioxide tension during 
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The patient compliance in taking the capsules was good, since in all male patients 
who received CMA, the testosterone levels decreased significantly (35 (±20) nmo|/l 
before CMA, and 15 (±15) nmol/l on CMA). On ACET the base excess shifted to a 
metabolic acidosis in all patients (mean decrease in base excess of 6.7 (SD 3.3) 
mmol/l (p <0.05)). 
After one week of ACET administration the mean serum creatinine levels increased 
from 92 to 94 umol/l, mean potassium levels decreased from 3.7 to 3.4 mmol/l and 
chloride levels increased from 98 to 100 mmo|/l (all: ρ <0.05). 
8.4.2. Ventilation 
The patients had low hypercapnic and hypoxic ventilatory responses as compared to 
normals, whereas the breathing frequency was rather high (table 8.3)(31, 32). 
The hypercapnic ventilatory response and minute ventilation significantly increased 
during CMA therapy. Beside the increase in hypercapnic ventilatory response, a 
considerable shift to the left was seen (fig 8.3). After ACET administration both the 
hypercapnic and the hypoxic ventilatory responses augmented. 
All the CMA patients and 16 out of the 18 ACET patients (89%) were able to 
decrease their PaC02 by at least 0.7 kPa by means of voluntary hyperventilation. 
8.4.3. Subjective parameters 
8.4.3.1. Beneficial effect 
In the CMA group 7 of the 18 patients (39%) said they benefited from this therapy. 
Seven of the 16 patients (41%) who had received ACET reported a favourable 
reaction. In the placebo group, 8 out of 18 patients (39%) claimed to feel better. 
Table 8.3 Effects of CMA, ACET and placebo on ventilation 
Differences (SD); results after minus before therapy 
CMA ACET Placebo 
HCVR (l/min/kPa) 
Н П (l/min/%) 
VE 0/min) 
VT(I) f 
a ρ < 0.05; comparison with data before therapy 
b ρ < 0.05; comparison to placebo 
HCVR: hypercapnic ventilatory response 
HVR: hypoxic ventilatory response 
VE: minute ventilation, VT: tidal volume, f: breathing frequency 
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1.0 (1.2Γ 
0.00 (0.2) 
2.2 (2.6)* 
0.05 (0.1) 
2.3 (2.8)·" 
1.0 (2.7)" 
0.12 (0.2)* 
0.0 (1.4) 
0.05 (0.2) 
-1.0 (2.9) 
0.2 (0.8) 
0.05 (0.1) 
0.1 (1.6) 
0.01 (0.1) 
-0.2 (2.4) 
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Figure .З The hypercapnic ventilatory responses before and after CMA and ACET are shown 
8.4.3.2. Side effects 
Three patients (17%) reported side effects during CMA therapy (vertigo, palpitations 
and stomach cramps). In the ACET group two patients complained about paraesthe-
sias in the fingertips, one of vertigo and one of nausea (24%). Three out of 18 patients 
(17%) in the placebo group complained about vertigo, nausea and increased 
dyspnoea. 
8.4.3.3. Subjective sleep quality 
The results of the St. Mary's Hospital sleep questionnaire are shown in table 8.4. CMA 
had no beneficial effect, whereas ACET therapy partly improved the subjective quality 
of sleep significantly: the majority of the patients reported to sleep better and longer 
during the night they were treated. This was comparable to the night with oxygen 
supplementation. Ignoring those patients, whose opinion did not change between 
treatments, we found that after the oxygen night 25 out of 40 patients reported deeper 
sleep, 27 out of 42 better sleep and 33 out of 51 longer sleep, though none of these 
changes appeared to be statistically significant. 
8.4.4. Nocturnal parameters (table 8.5) 
Mean nocturnal oxygen saturation improved substantially during ACET (5%) and 
oxygen (7%) therapy. During CMA treatment the mean Sa02 at night increased just a 
little (2%). No significant difference in the fall of nocturnal Pa0 2 as calculated from 
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Table 8.4 Results of the SMH sleep questionnaire during CMA, ACET, placebo and oxygen compared to room air 
During CMA During ACET During placebo During oxygen 
Better Worse Same Better Worse Same Better Worse Same Better Worse Same 
Depth of sleep 
(Q5#) 
Awakenings 
(06) 
Hours asleep 
(07) 
Value of sleep 
(09) 
Alertness in the 
morning (Q10) 
Early awake 
(011) 
Difficulty in falling 
asleep (Q12) 
2 
6 
7 
5 
6 
3 
4 
S 
7 
9 
8 
4 
5 
4 
11 
11 
2 
5 
8 
10 
10 
10 * 
9 
12 · 
10 * 
5 
7 
9 Г) 
3 
6 
3 
2 
5 
3 
2 
3 
1 
1 
4 
6 
6 
5 
1 
8 
5 
4 
6 
0 
2 
7 
7 
11 
5 
3 
4 
8 
10 
3 
2 
9 
9 
14 
8 
25 
26 
33 
27 
22 
13 
23 
15 
15 
18 
15 
11 
5 
14 
13 
12 
2 
11 
20 
35 
16 
* ρ < 0.05 comparison with room air night 
(*) 0.05 < ρ < 0.01 comparison with room air night 
# number of question in SMH questionnaire 
changes m Sa02 (Hill-equation) was observed during any of the therapies. CMA and 
ACET decreased the baseline P^COj values during sleep to the same extent (0.5 
kPa), whereas oxygen increased the PETC02 (0.3 kPa). The rise in PETC02 throughout 
the night did not significantly change during any of the treatments compared to the 
room air night. 
Oxygen supplementation decreased the total time of the night which was spent 
desaturated by 37 minutes (SD 52, ρ <0.05) and ACET treatment decreased the 
desaturation time by 30 minutes (SD 65, ρ >0.05). Eleven per cent (SD 19) of the 
desaturating episodes during the room air night was associated with apnoeas. Only 4 
out of the 53 patients (8%) experienced more than 5 apnoeas per hour of sleep. 
During the oxygen night an increased per cent of the desaturations was accompanied 
by apnoeas (21% (SD 38), ρ >0.05). During CMA and ACET administration a signifi­
cant decrease in apnoeas was shown from 14% to 3% (CMA) and from 11% to 0% 
(ACET). In the placebo group the per cent of desaturations caused by apnoeas 
remained the same (9%). 
During ACET treatment the total sleep time increased by 2.2 hour (SD 0.7) and the 
number of movement arousals decreased by 1.8 per hour (SD 4.6). CMA therapy had 
no beneficial effect on total sleep time or movement arousals. 
Table 8.5 Effects of CMA, ACET and oxygen on nocturnal parameters 
Differences (SD); results after minus before therapy 
Mean Sa0 2 (%) 
S D of mean Sa0 2 
Lowest 5аО
г
 (%) 
Fall in ЗаО
г
 (%) 
Fall in Pa0 2 (kPa) 
calculated 
4% dips 
Baseline PETCO; 
awake (kPa) 
Baseline Р^СО
г 
asleep (kPa) 
Highest P^COj 
asleep (kPa) 
Rise in PET-COJ 
Desaturation time (mm) 
Total sleep time (hrs) 
Movement arousals 
(per hours) 
CMA 
2 1 (3 5)a 
0 0 (0 9) 
0 7 ( 1 1 ) 
-0 8 (9.0) 
0.2 (0.8) 
0.1 (4.6) 
-0.5 (0.7)^ 
-0.5 (0.7)" 
-0.5 (О.Э"" 
0 0 (0 6) 
2 2(19) 
0 7 (1 3) 
2.1 (4.6) 
ACET 
4.3 (6.2)°"° 
-03(1.1) 
7 6(13 b 
-4.1 (9.6) 
0 4(1.0) 
-4.9 (8.1)1 
-0.5 (0.8)'b 
-0.4 (0.7)" 
-0.7 (0.9)'b 
-0.1 (0 8) 
-30 0 (65) 
2.2 (0 7)b 
-1 8 (4 6) 
Placebo 
0.3 (2 3) 
0.4 (1 1) 
-2 0(4) 
2.1 (4.2) 
0.2 (0.3) 
1.8(5 9) 
0.0 (0.3) 
-0.1 (0.5) 
-0.3(1.6 
0.1 (0.6) 
1.5(21) 
-0.9 (1.0) 
3 3 (7.0) 
o2 
7 4(7.6)"** 
-0 7(1.5)"1 
13.5 (12)""· 
-7.8 (8 9)""" 
0.4(1.4) 
-7.4 (6.7)'bd· 
0.3 (0.7)"* 
0.3 (0 8)·" 
0.5 (1.1)·"· 
0 2 (0.9) 
-36 5 (52)·" ' 
a ρ < 0 05: companson with data before treatment; 
b ρ < 0.05 comparison with placebo 
с ρ < 0.05. comparison ACET to CMA 
d ρ < 0 05: comparison 0 2 to ACET 
e ρ < 0.05: companson 0 2 to CMA 
Fall in SaOj baseline Sa0 2 awake minus lowest Sa0 2 asleep 
Fall in Pa0 2 calculated from Sa0 2 with Hill equation 
Rise in PgyCOj- baseline PETCOJ awake minus highest PETCOJ asleep 
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8.5. Discussion 
This study investigated the effects of CMA, ACET and 0 2 on awake and asleep blood 
gas values in a group of 53 hypoxaemic patients with COPD. The trial was 
randomised, double-blind and placebo-controlled. Thus suggestibility was minimized, 
information could be corrected for a possible placebo effect, and cross-over effects 
would not obscure the results. 
CMA and ACET therapy decreased day- and nighttime PC0 2 levels to a similar 
degree, whereas supplemental oxygen caused increased СО
г
 retention during the day 
and night. Awake and asleep oxygenation improved most with oxygen therapy, though 
ACET also achieved a significant substantial improvement. CMA had virtually no effect 
on SaOj. These findings are comparable with those of others (13, 17), though some 
investigators showed a more favourable effect of progesterone on nocturnal oxygen­
ation in a few selected COPD patients (11, 12, 16). No significant change was 
observed in the fall of the Pa02 or in the rise of the РЕ ТСОг throughout the night during 
any of the three therapies. This suggests that the improvement of the nocturnal Sa0 2 
observed during the three therapies, as well as the decrease of the Р
ЕТ
СО
г
 during 
CMA and ACET and the increase during oxygen supplementation were mostly due to 
different initial daytime blood gas values. In other words, nocturnal hypoventilation still 
occurred. This is consistent with the theory that the major cause of hypoventilation 
during REM sleep is the reduction in activity of the inspiratory muscles and that 
diminished chemical ventilatory responses, which may be influenced by respiratory 
stimulants, only play a minor role (1, 33, 34). 
It was observed in the patients with COPD, that fewer nocturnal desaturations were 
associated with apnoeas during CMA and ACET therapy compared to room air. These 
results are in agreement with findings in patients with the sleep apnoea syndrome 
(35-38). 
The subjective daytime benefit of both CMA and ACET was clearly a placebo effect 
since in all three groups the same percentage of patients felt better when taking any 
of the capsules. The side effects could also partly be explained by a placebo effect, 
though paraesthesia and nausea is probably a "true" side effect of ACET (12, 35, 36). 
In the placebo group a slight increase in awake РаО
г
 was observed. Probably this 
is the random fluctuation of a group of patients undergoing intensive study. The slight 
increase in hypoxic ventilatory response in the placebo group could be explained by 
the increased PaC02 (39). 
Some information about the mechanism of CMA and ACET could be obtained by 
evaluating the data about the resting ventilation, control of ventilation and acid-base 
status. CMA increased minute ventilation due to augmented hypercapnic ventilatory 
response, whereas the hypoxic ventilatory response remained unchanged. In this study 
the hypoxic ventilatory response during therapy was measured at "hypocapnic post-
drug" level. In some other studies the hypoxic ventilatory response was measured at 
the relatively high pretreatment Р^СОг levels. In these studies an increased hypoxic 
ventilatory response after progesterone treatment was observed (15,16). It has been 
suggested that progesterone stimulates ventilation via central chemoreceptors (10,18). 
The fact that in the current study CMA affected the hypercapnic ventilatory response 
without effect on the hypoxic ventilatory response supported this theory. Medroxypro­
gesterone can be expected to have similar effects (40). An indication of increased 
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alveolar ventilation on ACET therapy was shown by the trend in increased tidal volume 
and decreased breathing frequency (table 8.3). ACET inhibits carbonic anhydrase 
which is present in the carotid bodies (41) as well as in the glial cells near the central 
chemoreceptors (42). In this study the hypercapnic and hypoxic ventilatory responses 
were augmented by ACET. This is compatible with the notion that ACET apparently 
had an effect on both the peripheral and on the central receptors. In the literature the 
exact mechanism of ACET is not yet clear (19-21, 43). 
Skatrud et al, who studied the effects of medroxyprogesterone and ACET, divided 
his patients in correctors and non-correctors by using the criterion of a decrease of 
more or less than 0.67 kPa in daytime РаСО
г
 during treatment (10, 12). They sug­
gested that the non-correctors in their study had more severe obstructive airway 
disease (lower FEV, values) and more hyperinflation (higher FRC values) and were not 
able to lower their РаСО
г
 on voluntary hyperventilation. Furthermore, patients who 
increased tidal volume rather than respiratory rate would react more favourably to the 
respiratory stimulants. Neither in the CMA group nor in the ACET group of the current 
study a significant correlation could be established between the réponse of PaC02 and 
the severity of the obstruction (FEV, "/opredicted), the hyperinflation (FRC and RV 
%predicted), any of the other patient characteristics that were tested or the concomi-
tant response of the ventilation parameters. Apparently the response in our patients 
(mean FEV, 30% predicted) to the respiratory stimulating drugs used was not depend-
ent on ventilatory limitations. Indeed, all the CMA patients and 89% of ACET patients 
were able to decrease their PaC02 by at least 0.7 kPa by means of voluntary 
hyperventilation. Hence, we could not comfirm any of the possible predictors of 
responses to ventilatory stimulants that were suggested by the group of Skatrud (10, 
12). Neither could we find any other predicting characteristic. 
In order to assess the clinical value of CMA and ACET treatment, we checked how 
many patients attained an acceptable level of day- and nighttime oxygenation (Pa02 
awake > 8.5 kPa, mean nocturnal Sa02 > 90%) and carbon dioxide tension (PaC02 
awake < 6.0 kPa) with CMA or ACET administration. In three of the 18 patients (17%) 
treated with CMA and in 9 of the 17 patients (53%) treated with ACET, awake and 
asleep blood gases could be corrected sufficiently. Hence, in these 12 out of 35 
patients (34%) treated with CMA or ACET, expensive oxygen therapy was not necess-
ary. As expected, these 12 patients were just mildly hypoxaemic (mean Pa02 daytime 
8.1 kPa). Moreover, CMA or ACET therapy provides an useful alternative for hypo-
xaemic patients who do not want to be treated with oxygen at home. Furthermore, it 
has been shown by others that the decrease in PaC02 induced by CMA and ACET is 
the same, irrespective of breathing room air or oxygen (12). Therefore, CMA and 
ACET treatment may have additional value in hypoxaemic patients who are treated 
with oxygen suppletion, in order to correct the C02 retention caused by the oxygen 
therapy. Also patients with COPD who suffer from a sleep apnoea syndrome as well 
may benefit by CMA or ACET therapy. Oxygen in these patients may lead to severe 
C0 2 retention and acidosis (44). CMA and ACET as an alternative or additional 
treatment may correct the PaC02 and diminish the occurrence of apnoeas (35-38). 
It was concluded that in the group of patients with COPD, the effects of ACET 
treatment on gas exchange were favourable to those of CMA. Oxygen therapy 
improved oxygenation slightly more than ACET, but aggravated the C02 retention. 
Individual patients may benefit from CMA or ACET therapy as an alternative - or 
perhaps in addition - to oxygen supplementation. 
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Chapter 9 
Summary 

9.1. Introduction 
Patients with chronic obstructive pulmonary disease (COPD) may develop oxygen 
desaturations during sleep. These desaturations are mostly associated with hypoventi­
lation. Hypoventilation is caused by reduced intercostal- and accessory-muscle activity 
during the REM (Rapid-Eye-Movement) sleep state and the incapability of the dia­
phragm to compensate for this decreased activity. 
In the general introduction of this thesis breathing during sleep in healthy people 
and in patients with COPD is described. Furthermore, a review of the literature is given 
and the objectives of the current thesis are outlined. 
The specific aims of the studies described in this thesis were to examine: 
• the prevalence and severity of nocturnal oxygen desaturations in patients with 
COPD with a FEV, value below 65% of predicted, and the relation of the nocturnal 
oxygen saturation with daytime parameters (chapter 2); 
• the night-to-night variability of the nocturnal oxygen saturation and breathing pattern 
in COPD patients (chapter 3); 
• the prediction of nocturnal hypoxaemia in COPD patients with daytime normoxia 
or mild hypoxia (chapter 4); 
• the usefulness of continuous nocturnal end-tidal PC02 recording to detect hypoven-
tilation/hypopnoea (chapter 5); 
• the value of the video movement detector to indicate sleep times and movement 
arousals (chapter 6); 
• the selective attention, as a parameter of cognitive function, in COPD patients and 
the relation with day- and nighttime parameters (chapter 7); 
• the therapeutic effects of oxygen supplementation, Chlormadinone acetate and 
acetazolamide on awake and asleep gas exchange, breathing and sleep quality in 
COPD patients (chapter 8); 
9.2. Prevalence of nocturnal oxygen desaturations in 
patients with COPD 
In chapter 2 the prevalence and severity of nocturnal oxygen desaturations in COPD 
patients were investigated. In addition, the association with breathing disorders is 
examined. Sixty COPD patients participated in this study. They were all in a clinical 
stable condition. Their mean FEV, value was 34.2% (SD 11). The mean Pa02 of the 
group was 9.0 kPa (SD 1.5) and the mean РаСО
г
 5.7 kPa (SD1.0). "Desaturation" was 
defined as a decrease in Sa02 of at least 4%. 
Seventy-eight per cent of the patients developed nocturnal desaturations. Their 
mean nocturnal Sa02 was 88.5%, varying from 69 to 96%. The lowest nocturnal Sa02 
in this group was 77.8% (range 48 to 90%). The COPD patients with nocturnal 
desaturations had significantly lower FEV, values (33 and 40% respectively, ρ < 0.05) 
and lower hypercapnic ventilatory responses (3.3 and 6.0 l/min/kPa respectively, 
p-0.06) than those without desaturations. No significant difference could be found in 
daytime blood gas values between these two groups. 
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At a group level (all 60 patients), the daytime Sa02 (r-0.78), Pa02 (r-0.79), PaC02 
(r--0.57), and the hypercapnic ventilatory response (r-0.40) correlated significantly with 
the mean nocturnal Sa02 as well as with the lowest nocturnal Sa02. Nevertheless 
between individual patients the variation was large; patients with a daytime Sa02 of 
90% could have a mean nocturnal Sa02 varying from 82 to 89%. So, if one wants to 
know precisely the nocturnal saturation of an individual patient, one has to measure 
during the night. Eighty-three per cent of the episodes with desaturations were 
associated with hypoventilation and seventeen per cent with apnoeas. 
9.3. "First-night effect" 
In chapter 3 the study about the night-to-night variability of oxygen saturation and 
breathing parameters in patients with COPD is described. A first-night effect in 
neurophysiological variables (EEG) in normal subjects has been shown in several 
studies. Not much is known about the influence of this first-night effect on the oxygen 
saturation and breathing pattern in COPD patients. Therefore, fifteen patients with 
COPD were studied on two consecutive nights and in sixteen other COPD patients 
sleep studies were performed on two nights one week apart. 
The mean nocturnal Sa02 in the group patients studied on two consecutive nights 
was 89% (SD 5.6) during the first night and 89% (SD 4.9) during the second night. In 
the group of patients studied on two non-consecutive nights the mean nocturnal Sa02 
was 86% (SD 4.3) and 87% (SD 3.1) respectively. No significant differences were 
found in disordered breathing of the first and second night in either situation. 
It was concluded that one night's recording is sufficient to characterise the oxygen 
saturation and breathing pattern in COPD patients. 
9.4. Predictors for nocturnal hypoxaemia 
(mean SaO2<90%) in normoxic or mild hypoxic 
patients with COPD 
In chapter 4 the prevalence of nocturnal hypoxaemia (defined as a mean Sa02 below 
90%) in COPD patients with a daytime arterial P02 above 8 kPa is determined. 
Nocturnal hypoxaemia in these patients may be a predecessor of pulmonary hyperten-
sion. Fourty-two patients with COPD were examined. Their mean FEV1 value was 35% 
(SD 10). The mean Pa02 during the day was 9.8 kPa (SD 1.1) and the mean PaC02 
was 5.4 kPa (SD 0.7). 
In ten patients (24%) enough desaturations occurred to develop nocturnal hypo-
xaemia. These ten patients had a significantly younger age (66 to 68 years), lower Pa02 
values (9.1 to 10 kPa), higher PaC02 values (5.8 to 5.3 kPa) and lower hypercapnic 
ventilatory responses (2.1 to 4.9 1/min/kPa). Furthermore, more patients with nocturnal 
hypoxaemia smoked (50 to 16%) and complained about daytime sleepiness (60 to 12%). 
Multiple linear regression analysis demonstrated that only daytime Pa02 (32%) and the 
hypercapnic ventilatory response (5%) contributed independently to the prediction of the 
mean nocturnal Sa02. Though only 37% of its total variance could be explained. 
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In this study none of the patients with a daytime Pa0 2 > 11 kPa developed 
nocturnal hypoxaemia. The value of the hypercapnic ventilatory response as a 
screening parameter was examined in the other patients. Only patients with a low 
response (<3.5 l/mm/kPa) were considered to run a risk of developing nocturnal 
hypoxaemia Only those patients should be measured during the night. The sensitivity 
was 80% and the specificity 70% Practically this means that m the group patients 
studied two patients with nocturnal hypoxaemia (20%) would be missed and eight 
patients without nocturnal hypoxaemia (22%) would be measured unnecessarily. 
9.5. Nocturnal end-tidal PC02 recordings in patients with 
COPD or sleep apnoea syndrome 
In chapter 5 a study of the nocturnal continuous measurement of end-tidal PC0 2 is 
presented The end-tidal PC02was measured during sleep by introducing a cannula in 
the oronasal cavity. This cannula was connected to a capnograph. The usefulness of 
this method to detect hypoventilation/hypopnoea and apnoeas was studied Twenty-
nine patients with COPD were measured one night during room air and one night 
during oxygen supplementation. The mean daytime РаО
г
 of these patients was 7.5 
kPa (SD 1.1) Furthermore, 19 subjects who were referred to the sleep laboratory for 
snoring and daytime sleepiness participated in this study. 
The results showed that 26 patients with COPD developed 67 episodes with 
nocturnal oxygen desaturations which were all accompanied by an increased Р
е т
СО
г 
indicating hypoventilation Three episodes of desaturations were also accompanied by 
apnoeas During 24 of the episodes with desaturations (36%) no change was found in 
the thoracic abdominal movement as measured simultaneously with inductive plethys­
mography During oxygen therapy nocturnal episodes with increased Р
ЕТ
СО
г
, thus 
hypoventilation, occurred in all 29 COPD patients. Only some of these episodes were 
accompanied by oxygen desaturations. 
In the 19 subjects who were suspected to have obstructive breathing, apnoeas as 
well as hypopnoeas could easily be assessed with the Р
ЕТ
СО
г
 signal Also short 
apnoeas and hypopnoeas and those accompanied by only small dips in oxygen 
saturations could be detected. Nine persons (47%) developed an apnoea/hypopnoea 
index above ten. 
The conclusion of this study was that continuous recording of PET C0 2 during sleep 
was a valuable method to detect apnoeas and hypoventilation/hypopnoeas in COPD 
patients with and without oxygen supplementation and in people suspected to have a 
sleep apnoea syndrome. 
9.6. The value of the video movement detector 
Chapter 6 describes the usefulness of overnight video recordings to determine sleep 
times and movement arousals. An automated system to log movement from video 
recordings was developed. Definitions were assessed for "sleep", "awake" and 
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"movement during sleep" Its value was evaluated in eighteen patients, who were 
referred to the sleep laboratory for various sleep problems The results of the conven-
tional sleep analysis (EEG, EOG and EMG) were considered to be the gold standard 
The tracings were analysed blind from each other 
There was no significant difference between the conventional sleep analysis and 
the video movement device with respect to total sleep time, sleep onset, "wake after 
sleep onset" and awake time The number of movement arousals (> 2 seconds) 
detected by the video method correlated very well with those documented by the 
conventional sleep analysis (r - 0 99) Furthermore, the results of the video movement 
technique were reproducible 
It was concluded that the video movement detector indicates sleep times and 
movement arousals fairly well and for this aim it is an alternative for the conventional 
sleep analysis for instance in case such an analysis is not available 
9.7. Attention in patients with COPD 
In chapter 7 the study about the selective attention, a parameter of cognitive function, 
in COPD patients is presented In 39 patients with COPD this selective attention was 
measured by means of the Bourdon-Vos test and it was compared with the attention 
performance of 38 healthy controls of the same age range. The correlation of the 
attention of COPD patients with day- and nighttime parameters was determined. 
Moreover, in 44 other COPD patients with daytime hypoxaemia, the effect on attention 
performance of one night of oxygen supplementation and of a seven-day treatment 
with the respiratory stimulants Chlormadinone acetate or acetazolamide, was studied. 
The results showed that the attention performance of the COPD patients was 
significantly lower than that of the controls of the same age range The mean line time 
of the group of COPD patients was 14 1 seconds (SD 3) and the line time of the 
healthy people was 12 6 seconds (SD 2) 
A significant correlation was found between the attention of COPD patients and age 
(r-0 33), vital capacity (r—0 31), hypercapmc ventilatory response (r--0 43), daytime 
Sa02 (r--0 33), daytime PaOz (r--0 28), daytime PaC02 (r-0 31), mean nocturnal Sa02 
(r=-0 33) and lowest nocturnal Sa02 (r--0 33) Multiple linear regression analysis 
showed that, beside age (11%), only the nadir of the nocturnal Sa02 (9%) contributed 
independently to the prediction of the attentron. 
No clinically important short-term effect of oxygen supplementation or respiratory 
stimulation could be assessed. 
9.8. Effects of oxygen supplementation, 
Chlormadinone acetate and acetazolamide in 
patients with COPD 
In chapter 8 the effects of clormadinone acetate (CMA), acetazolamide (ACET) and 
oxygen supplementation on awake and asleep blood gas values, on breathing and on 
sleep quality are described The study was designed as a double-blind, placebo-
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controlled, randomised trial. Fifty-three hypoxaemic patients with COPD were studied. 
Their mean FEV, was 30% (SD10). Their mean daytime Pa02 was 7.4 kPa (SD 1.0) 
and the mean PaCOz was 6.4 kPa (SD 1.2). The first two consecutive nights all 
patients received either room air or oxygen, via a nasal cannula, in random order. Next 
they received either CMA (25 mg), or ACET (250mg) or placebo twice a day for a 
period of one week, all in identical capsules. 
CMA as well as ACET therapy decreased the РСО
г
 level during day and night to 
the same extent. Oxygen supplementation increased the day- and nighttime РСО
г
. 
ACET and oxygen supplementation improved the oxygenation substantially. During 
CMA and ACET therapy the hypercapnic ventilatory response augmented significantly 
as compared to placebo. The hypoxic ventilatory response increased only significantly 
during ACET administration. Subjective sleep quality improved significantly during 
ACET therapy and did not improve during CMA or oxygen therapy. The most important 
results are shown in table 9.1. 
The effects of CMA and ACET for the individual patients were as follows. Seven­
teen per cent of the hypoxaemic patients with COPD treated with CMA, and even 53% 
of the patients treated with ACET attained an acceptable level of day- and nighttime 
oxygenation and carbon dioxide level. The effect of either respiratory stimulant on 
PaCOj or Pa02 was not correlated with pulmonary function parameters, ventilatory 
responses or initial blood gas levels. Hence, patients who did react well upon CMA or 
ACET, could not be distinguished from those who did not react well. 
The beneficial effect of CMA and ACET on the C02 retention (and on apnoeas) 
may provide a future additional therapy in those patients with COPD (with or without 
a sleep apnoea syndrome) who develop severe C02 retention during oxygen supple­
mentation. 
Table 9.1 The effects of CMA, ACET and 0 2 therapy 
Pa0 2 daytime (kPa) 
PaCOj daytime (kPa) 
Sa0 2 nighttime (%) 
P ^ O j nighttime (kPa) 
HCVR (l/min/kPa) 
HVR (l/min/%) 
Roomair 
7.4 
6.4 
85 
5.4 
2.3 
0.2 
CMA 
7.8* 
5.β* 
84' 
4.7* 
3.3* 
0.2 
ACET 
9.4*" 
5.9" 
89*^ 
5.0* 
З.Т" 
0.3" 
o2 
9.9·^ 
7.0**· 
9 2 · " · 
5 . 7 * * 
a ρ < 0.05; comparison with data before therapy 
b ρ < 0.05; comparison to placebo 
с ρ < 0.05; comparison ACET to CMA 
d ρ < 0.05; comparison О
г
 to ACET 
e ρ < 0.05; comparison О
г
 to ACET 
HCVR: hypercapnic ventilatory response 
HVR: hypoxic ventilatory response 
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9.9. Conclusions 
• Seventy-eight per cent of the patients with COPD studied developed nocturnal 
oxygen desaturations. 
• Eighty-three per cent of these desaturations were associated with hypoventilation 
• No significant difference in daytime blood gas values was found between COPD 
patients with and without oxygen desaturations. 
• In the group of COPD patients the nocturnal Sa02 was significantly correlated with 
the daytime 5аО
г
, РаО
г
, PaC02 and the hypercapnic ventilatory response. Yet, 
none of these correlations appeared strong enough to predict the nocturnal oxygen 
saturation in the individual patient precisely. Therefore, overnight recordings will 
remain necessary to be exactly informed about the nocturnal oxygen saturation in 
the individual patient. 
• A single night's recording appeared reliable enough to characterise the nocturnal 
oxygen saturation and breathing pattern in patients with COPD. 
• Twenty-four of the COPD patients with a daytime РаО
г
 of at least 8 kPa developed 
nocturnal hypoxaemia (mean nocturnal Sa02 < 90%). 
• None of the patients with a Pa02 above 11 kPa developed nocturnal hypoxaemia. 
Measurement of the hypercapnic ventilatory response appeared helpful to indicate 
nocturnal hypoxaemia in COPD patients with daytime РаО
г
 < 11 kPa and > 8 kPa. 
Patients with higher hypercapnic ventilatory response value were less likely to 
develop nocturnal hypoxaemia. 
• Gontinous recording of PETC02 during sleep was a valuable method to detect 
apnoeas and hypoventilation/hypopnoeas in COPD patients with and without 
oxygen supplementation and in people suspected to have a sleep apnoea syn­
drome. 
• The video movement analyser identified sleep times and movement arousals 
adequately enough to be useful in clinical pulmonary practice as an alternative 
method in this respect when conventional sleep analysis is not available. 
• The selective attention of COPD patients was low compared to controls of the 
same age range. Except age only the lowest nocturnal Sa02 was independently 
related to the attentbn performance of patients with COPD. 
• Chlormadinone acetate and acetazolamide decreased the РСО
г
 level during day-
and nighttime to the same extent. 
• The effect of one week of acetazolamide on awake and asleep oxygenation and on 
the subjective quality of sleep was better than that of Chlormadinone acetate. 
• Acetazolamide as well as oxygen supplementation improved oxygenation. 
- Oxygen therapy increases day- and nighttime PC02 levels and had no significant 
effect on sleep quality. 
• Seventeen per cent of the hypoxaemic patients with COPD treated with Chlormadi­
none acetate, and 53% of the patients treated with acetazolamide attained an 
acceptable level of day- and nighttime oxygenation and carbon dioxide level. 
• COPD patients who did react well upon Chlormadinone acetate or acetazolamide, 
could not be distuinguished from those who did not react well, making use of the 
pulmonary function, the hypercapnic and hypoxic ventilatory responses or blood 
gas values during the day. 
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Chapter 10 
Samenvatting 

10.1. Inleiding 
Bij patiënten met een chronisch obstructief longlijden (COPD) kunnen zuurstofdesatura-
ties optreden tijdens de slaap. Deze worden voornamelijk veroorzaakt door hypoventi-
latie. Hypoventilatie treedt op ten gevolge van verminderde activiteit van de intercostaal 
en accessoire inademingsspieren tijdens het REM (Rapid-Eye-Movement) slaap 
stadium in combinatie met het onvermogen van het diafragma om deze vermindering 
in activiteit te compenseren. 
De inleiding van dit proefschrift beschrijft de ademhaling tijdens de slaap bij 
gezonden en bij COPD-patiënten gebaseerd op gegevens uit de literatuur (hoofdstuk 
1). Hieruit vloeiden de vraagstellingen voort die de basis waren voor de studies van dit 
proefschrift. 
De specifieke doelstellingen van dit proefschrift waren het onderzoeken van: 
• de prevalentie en de ernst van nachtelijke zuurstofdesaturaties bij COPD-patiënten 
met een éón-seconde-waarde lager dan 65 procent van de voorspelde waarde, en 
de relatie tussen de nachtelijke zuurstofsaturatie en diverse parameters overdag 
(hoofdstuk 2); 
• de variabiliteit van het zuurstofsaturatie- en ademhalingspatroon van COPD-
patiënten gedurende twee nachten (hoofdstuk 3); 
• de voorspelling van nachtelijke hypoxaemie bij COPD-patiënten met een normoxie 
of een milde hypoxie overdag (hoofdstuk 4); 
• het nut van continue nachtelijke P^COj-meting om hypoventilatie/hypopnoes vast 
te stellen (hoofdstuk 5); 
• de waarde van het video-bewegingssysteem om slaaptijden en bewegings-arousals 
aan te geven (hoofdstuk 6); 
• de selectieve aandacht, als parameter van de cognitieve functie, bij COPD-patiën-
ten en de relatie met diverse parameters overdag en 's nachts (hoofdstuk 7); 
• de effecten van zuurstofsuppletie, chbrmadinon-acetaat en acetazolamide op de 
gaswisseling en ademhaling overdag en 's nachts van COPD-patiënten (hoofdstuk 
8); 
10.2. Prevalentie van nachtelijke zuurstofdesaturaties 
bij COPD-patiënten 
Hoofdstuk 2 beschrijft de studie naar de prevalentie en de ernst van nachtelijke 
zuurstofdesaturaties bij COPD-patiënten. Verder is de relatie tussen de nachtelijke 
zuurstofsaturatie en diverse parameters overdag onderzocht. Zestig patiënten met 
COPD participeerden aan deze studie. Allen waren in een klinisch stabiele fase. Zij 
hadden een gemiddelde FEV,-waarde van 34.2 procent (SD 11.0). De gemiddelde 
Pa02 bedroeg 9.0 kPa (SD 1.5) en de gemiddelde РаСО
г
 5.7 kPa (SD 1.0). 'Desatura-
tie' werd gedefinieerd als een daling in Sa02 van tenminste vier procent. 
Dit onderzoek leidde tot de volgende resultaten. 47 Van de zestig patiënten (78 
procent) ontwikkelden één of meerdere zuurstofdesaturaties tijdens de slaap. 83 
Procent van de nachtelijke desaturaties waren geassocieerd met hypoventilatie en 
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zeventien procent met apnoes. De gemiddelde nachtelijke zuurstofsaturatie van de 
patiënten mèt desaturaties bedroeg 88.5 procent, variërend van 69 tot 96 procent. De 
laagste nachtelijke Sa02 was gemiddeld 77.8 procent, variërend van 48 tot negentig 
procent. De COPD-patiënten mèt nachtelijke desaturaties hadden een lagere FEV,-
waarde (respectievelijk 32.5 en 40.4 procent, ρ < 0.05) en een lagere hypercapnische 
ventilatoire respons (respectievelijk 3.3 en 6.0 1/min/kPa, ρ - 0.06) dan de patiënten 
zónder desaturaties. Er bestond géén significant verschil in bloedgaswaarden overdag 
tussen deze twee groepen. 
Op groepsniveau (alle zestig patiënten) bestond er een significante correlatie 
tussen de gemiddelde nachtelijke zuurstofsaturatie en de Sa02 (r-0.78), de Pa02 
(r-0.79), de PaC02 (r--0.57) en de hypercapnische ventilatoire respons (r-0.40) 
overdag. Ook was er een significante correlatie tussen de laagste Sa02-waarde 
gedurende de nacht en de bovengenoemde parameters overdag. Desalniettemin bleek 
de spreiding tussen de patiënten groot; patiënten met een Sa02-waarde overdag van 
negentig procent hadden een gemiddelde nachtelijke Sa02 variërend van 82 tot 89 
procent. Dit betekent dus dat men 's nachts moet meten, wil men precies geïnformeerd 
zijn over de nachtelijke zuurstofsaturatie van een bepaalde patiënt. 
10.3. 'Eerste-nacht-effect' 
In hoofdstuk 3 komt het onderzoek naar het 'eerste-nacht-effect' aan bod. Dit effect 
houdt in dat de neurofysiologische parameters (EEG) van de eerste nacht waarin een 
polysomnografie wordt gemaakt, verschillen van die van de tweede nacht. Er is weinig 
bekend over de invloed van dit 'eerste-nacht-effect' op het zuurstofsaturatie- en 
ademhalingspatroon van COPD-patiënten. In deze studie werden vijftien COPD-
patiënten tijdens twee opeenvolgende nachten bestudeerd en zestien andere COPD-
patiënten gedurende twee nachten met één week tussenpauze. 
De leidde tot de volgende resultaten. De gemiddelde nachtelijke Sa02 in de groep 
patiënten die twee opeenvolgende nachten werd onderzocht, bedroeg 89 procent (SD 
5.6) gedurende de eerste nacht en 89 procent (SD 4.9) in de tweede nacht. In de 
groep die gedurende twee niet-opeenvolgende nachten werd bestudeerd, was de 
gemiddelde nachtelijke Sa02 respectievelijk 86 procent (SD 4.3) en 87 procent (SD 
3.1). Noch in de situatie van de twee opeenvolgende nachten, noch in die van de twee 
niet-opeenvolgende nachten was er een significant verschil in ademhalingsstoornissen. 
Geconcludeerd mag worden dat meting gedurende één nacht voldoende betrouw-
baar het zuurstofsaturatie- en ademhalingspatroon aangeeft. 
10.4. Voorspelling van nachtelijke hypoxaemie bij 
COPD-patiënten met normoxie of milde hypoxie 
overdag 
Hoofdstuk 4 gaat over het onderzoek naar het voorspellen van nachtelijke hypoxaemie 
bij COPD-patiënten die overdag een arteriële P02 waarde hebben van acht kPa of 
meer. Nachtelijke hypoxaemie bij deze patiënten is mogelijk een voorloper van de 
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ontwikkeling van pulmonale hypertensie. Nachtelijke hypoxaemie werd in deze studie 
gedefinieerd als een gemiddelde nachtelijke Sa02 beneden negentig procent. 42 
COPD-patiënten, in een klinisch stabiele fase, participeerden in dit onderzoek. De 
gemiddelde FEV,-waarde van de groep was 35 procent (SD 9.9). De gemiddelde Pa02 
overdag bedroeg 9.8 kPa (SD 1.1) en de gemiddelde РаСО
г
 5.4 kPa (SD 0.7). 
Dit onderzoek leidde tot de volgende resultaten. Bij tien patiënten (24 procent) 
kwamen zoveel nachtelijke zuurstofdesaturaties voor dat de gemiddelde nachtelijke 
zuurstofsaturatie lagerwas dan negentig procent. Deze tien patiënten waren significant 
jonger (66 tegenover 68 jaar), hadden een lagere Pa02 overdag (9.1 tegenover 10.0 
kPa), een hogere PaC02 (5.8 tegenover 5.3 kPa) en een lagere hypercapnische 
ventilatoire respons (2.1 tegenover 4.9 ymm/kPa). Verder rookten zij vaker (vijftig 
procent tegenover zestien procent) en rapporteerden vaker slaperigheidsklachten 
(zestig procent tegenover twaalf procent). Het verschil tussen de groepen was evenwel 
zo klein en de overlap zo groot dat met deze parameters discriminatie tussen de 
groepen niet mogelijk was. Multipele lineaire regressie-analyse liet zien dat alleen de 
PaOj overdag (32 procent) en de hypercapnische ventilatoire respons (vijf procent) 
onafhankelijk correleerden met de nachtelijke gemiddelde Sa02. Doch samen konden 
zij slechts 37 procent van de totale variantie verklaren. 
Geen van de patiënten met een Pa02 overdag boven de elf kPa uit deze studie, 
ontwikkelde nachtelijke hypoxaemie. Bij de overige patiënten werd de waarde van de 
hypercapnische ventilatoire respons als screening test onderzocht. Alleen patiënten 
met een lage hypercapnische ventilatoire respons (< 3.5 l/min/kPa) werden veronder-
steld mogelijk 's nachts hypoxaemisch te worden. In dat geval zouden in de toekomst 
alleen deze patiënten een nachtelijk onderzoek hoeven ondergaan. De sensitiviteit van 
deze test was tachtig procent en de specificiteit zeventig procent. Practisch betekent 
dit dat in deze groep patiënten twee mensen (twintig procent) mèt nachtelijke hypoxae-
mie gemist zouden worden en acht mensen (22 procent) onnodig gemeten zouden 
worden. 
10.5. Nachtelijke end-tidal PC02-metmg bij COPD-patiën-
ten en patiënten met een slaapapnoe-syndroom 
In hoofdstuk 5 staat de studie centraal naar het nut van continue nachtelijk PETC02-
meting voor het opsporen van hypoventilatie/hypopnoes en apnoes. PETC02 is bepaald 
tijdens de slaap met een cannule die via de neus in de naso-orale holte ligt. De 
cannule is aangesloten op een capnograaf. Deze methode is gebruikt bij 29 COPD-
patiënten gedurende één nacht zónder extra zuurstofsuppletie en gedurende één nacht 
mèt zuurstofsuppletie. De gemiddelde Pa02 overdag van deze COPD-patiënten 
bedroeg 7.5 kPa (SD 1.1). Verder werden met deze methode negentien personen 
onderzocht die naar het slaaplaboratorium waren verwezen wegens snurk- en slaperig-
heidsklachten. 
Het onderzoek liet de volgende resultaten zien. 26 Van de 29 COPD-patiënten 
(89.6 procent) ontwikkelden in totaal 67 nachtelijke zuurstofdesaturaties die alle 
gepaard gingen met stijgingen van het P^CO^signaal wijzend op hypoventilatie. Drie 
van de nachtelijke zuurstofdesaturaties (5 procent) gingen mede gepaard met apnoes. 
Tijdens 24 episodes met desaturaties (36 procent) kon geheel geen verandering 
119 
waargenomen worden in de thoraco-abdominale beweging zoals tegelijkertijd gemeten 
werd met inductie-plethysmografie. Tijdens zuurstofsuppletie was er bij alle 29 COPD-
patiënten een toename van het basale P^Oj-niveau te zien met daarop gesuperpo-
neerd episoden van extra PETC02 stijging, dus hypoventilatie. Deze episoden gingen 
slechts in enkele gevallen gepaard met zuurstofdesaturaties. 
In de negentien personen met mogelijk obstructief gestoorde ademhaling tijdens de 
slaap, toonde de PerCOj-meting de apnoes alsmede de hypopnoes aan. Ook korte 
apnoes/hypopnoes en die hypopnoes die met slechts lichte desaturaties gepaard 
gingen kwamen aan het licht. Negen personen (47 procent) hadden een apnoe/hypop-
noe index boven de tien. 
De conclusie van dit onderzoek is dat continue nachtelijke PE1C02-meting een 
bruikbare methode is ter vaststelling van apnoes en hypoventilatie/hypopnoes bij 
COPD patiënten mèt en zónder zuurstofsuppletie en bij personen verdacht voor een 
slaapapnoe/hypopnoe-syndroom. 
10.6. De waarde van een video-bewegingsdetector 
Hoofdstuk 6 gaat over de waarde van de video-bewegingsdetector voor het vaststellen 
van slaaptijden en bewegings-arousals. Het is een automatisch systeem dat bewegin-
gen van video-opnames vastlegt. Hieruit kan 'slapen', "wakker zijn' en 'bewegen tijdens 
slaap' onderscheiden worden. De resultaten van de video-bewegingsdetector werden 
blind vergeleken met de resultaten van de conventionele slaapanalyse (EEG, EOG en 
EMG) bij achttien patiënten. Deze patiënten waren naar het slaaplaboratorium verwe-
zen wegens slaperigheidsklachten. 
Dit vergelijkend onderzoek leverde de volgende resultaten op. Er was geen 
significant verschil tussen de resultaten van de conventionele methode en de video-
methode wat betreft 'inslaaptijd', 'tijd wakker na inslapen', 'ontwaaktijd' en 'totale 
slaaptijd'. Het aantal bewegings-arousals (> 2 seconden) dat gedetecteerd werd met 
de video-methode correleerde zeer goed met het werkelijke aantal zoals aangegeven 
met de conventionele methode (r=0.99). Bovendien bleek de video-bewegingsdetector 
reproduceerbare slaaptijden en bewegings-arousals aan te geven. 
Geconcludeerd mag worden dat de video-methode een goede indruk geeft van 
slaaptijden en bewegings-arousals en in deze een alternatief vormt in geval conventio-
nele EEG slaapanalyse niet gewenst danwei niet beschikbaar is. -
10.7. Selectieve aandacht bij COPD-patiënten 
In hoofdstuk 7 is de selectieve aandacht, als parameter van de cognitieve functie, bij 
COPD-patiënten bestudeerd. De selectieve aandacht, zoals gemeten met de Bourdon-
Vos test, van 39 COPD-patiënten is vergeleken met de aandachtsresultaten van 38 
gezonde personen van dezelfde leeftijd. Ook is bij deze patiënten de relatie tussen de 
aandacht en diverse parameters 's nachts en overdag bepaald. Bovendien werd in 44 
andere hypoxaemische COPD-patiënten het effect bestudeerd op de aandacht van 
zuurstofsuppletie en een zevendaagse behandeling met ademhalingsstimulantia 
(chlormadinon-acetate en acetazolamide). 
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De resultaten lieten zien dat de selectieve aandacht van COPD-patiënten significant 
slechter was dan die van gezonde leeftijdsgenoten. De gemiddelde regeltijd van de 
COPD-groep bedroeg 14.1 seconde (SD 3.0) tegenover 12.6 seconden (SD 2.0) in de 
groep gezonden. 
De aandachtvan de COPD-patiënten correleerde significant met de leeftijd (r-0.33), 
vitale capaciteit (r—0.31), Sa02 overdag (r—0.33), Pa02 overdag (r—0.28), PaC02 
overdag (r-0.31), de hypercapnische ventilatoire respons (Г--0.43), de gemiddelde 
nachtelijke Sa02 (r=-0.33) en de laagste nachtelijke Sa02 (r—0.33). Multipele lineaire 
regressie-analyse liet zien dat behalve de leeftijd (elf procent) alleen de laagste 
nachtelijke Sa02-waarde (negen procent) onafhankelijk bijdroeg aan de voorspelling 
van de selectieve aandacht. 
Er kon geen korte-termijns-effect op de aandacht aangetoond worden van de drie 
genoemde therapeutische interventies. 
De belangrijkste conclusies van deze studie zijn dat COPD-patiënten een slechtere 
selectieve aandacht hebben dan gezonde leeftijdsgenoten en dat behalve leeftijd alleen 
de laagste zuurstofsaturatie 's nachts onafhankelijk bijdraagt aan de voorspelling van 
de selectieve aandacht. 
10.8. Effecten van zuurstofsuppletie, chlormadinon-
acetaat en acetazolamide bij COPD-patiënten 
Hoofdstuk 8 beschrijft een dubbelblinde, placebo gecontroleerde gerandomiseerde 
studie. Het doel van deze studie was het effect vast te stellen van zuurstofsuppletie, 
chlormadinon-acetaat (CMA) en acetazolamide (ACET) op de gaswisseling en adem-
haling overdag en 's nachts. 53 Hypoxaemische COPD-patiënten deden mee. Zij 
hadden een gemiddelde FEV,-waarde van 30.3 procent (SD 9.9). De gemiddelde Pa02 
overdag van de onderzochte groep was 7.4 kPa (SD 1.0) en de gemiddelde PaC02 
was6.4kPa (SD 1.2). 
Alle patiënten ontvingen gedurende de eerste twee opeenvolgende nachten 
kamerlucht danwei zuurstof via een nasale cannule, in gerandomiseerde volgorde. 
Vervolgens kregen zij gedurende een week, of CMA (25 mg), of ACET (250 mg) of 
placebo, tweemaal daags, in identieke capsules. 
Het onderzoek leidde tot de volgende resultaten. Op groepsniveau verlaagden 
zowel CMA als ACET therapie in gelijke mate de PC02 overdag en 's nachts. Zuurstof-
suppletie deed de PC02 substantieel stijgen. Het gunstige effect van ACET op de 
oxygenatie overdag was vergelijkbaar met zuurstofsuppletie, maar groter dan dat van 
CMA. 
Tijdens CMA- en ACET-therapie steeg de hypercapnische ventilatoire respons 
significant t.o.v. placebo. De hypoxische ventilatoire respons steeg alleen significant 
tijdens de ACET-behandeling. De subjectieve slaapkwaliteit verbeterde significant 
tijdens ACET-toediening en niet gedurende CMA- of zuurstoftherapie. Tijdens ACET-
toediening nam de totale slaaptijd toe en verminderde het aantal nachtelijke bewe-
gings-arousals. Tabel 10.1 laat de belangrijkste resultaten zien. 
Het effect van CMA of ACET gaf voor de individuele patiënten het volgende 
resultaat. Zeventien procent van de onderzochte hypoxaemische COPD-patiënten 
bereikte onder CMA-therapie acceptabele P02- en PC02-niveaus, en zelfs 53 procent 
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van de patiënten die met ACET werden behandeld. Het effect van CMA en ACET op 
PaC02 en Pa02 was niet afhankelijk van de longfunctie, de ventilatoire responsen op 
hypercapnie en hypoxie of de bloedgaswaarden overdag. Dit betekent dat patiënten die 
gunstig reageerden op CMA of ACET niet onderscheiden konden worden van degenen 
die niet goed reageerden. 
Tabel 10.1 De effecten van CMA, ACET en 02 therapie 
Pa02 overdag (kPa) 
PaCO., overdag (kPa) 
Sa02 's nachts (%) 
Р^СОг 's nachts (kPa) 
HCVR (l/min/kPa) 
HVR (l/min/%) 
Kameriucht 
7.4 
6.4 
85 
5.4 
2.3 
0.2 
CMA 
^ θ " 
5.8·" 
84* 
4.7* 
3.3** 
0.2 
ACET 
9 . 4 -
5.9* 
8 9 -
5.0* 
3.7* 
0.3' 
o2 
э.э*
11
· 
7.0*"* 
92*"· 
5.7*"' 
a ρ < 0.05; vergeleken met de data voor de therapie 
b ρ < 0.05; vergeleken met de data tijdens placebo 
с ρ < 0.05; data tijdens ACET vergeleken met die tijdens CMA 
d ρ < 0.05; data tijdens 0 2 vergeleken met die tijdens ACET 
e ρ < 0.05; dat tijdens 0 2 vergeleken met die tijdens CMA 
HCVR: hypercapnische ventilatoire respons 
HVR: hypoxische ventilatoire respons 
Overigens biedt het gunstige effect van ACET en CMA op de C02-retentie (en apnoes) 
perspectieven als mogelijke additionele therapie bij COPD-patiënten (met en zonder 
slaapapnoe-syndroom) die met 02-suppletie een te hoge C02-retentie ontwikkelen. 
Deze studie leidde tot de volgende conclusies. Op groepsniveau verbetert zowel 
CMA als ACET de PaC02 tot een zelfde niveau, echter op de oxygenatie heeft ACET 
een veel gunstiger effect dan CMA. Zuurstoftherapie heeft een ongunstig effect op de 
PaC02. Bij zeventien procent van de patiënten wordt met CMA een voldoende P02- en 
PC02-niveau bereikt en bij 53 procent met ACET. 
10.9. Conclusies 
• 78 Procent van de onderzochte COPD-patiënten ontwikkelde nachtelijke zuurstof-
desaturaties. 
• Deze desaturaties waren in 83 procent van de gevallen geassocieerd met hypoven-
tilatie. 
• COPD-patiënten met en zonder nachtelijke desaturaties waren niet te onderschei-
den met behulp van hun bloedgaswaarden overdag. 
• Op groepsniveau was de nachtelijke zuurstofsaturatie significant gecorreleerd met 
de SaOj overdag, de Pa02 overdag, de PaC02 overdag en de hypercapnische 
ventilatoire respons. Geen van deze correlaties bleek sterk genoeg om de nachtelij-
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ke saturatie van een bepaalde patiënt precies genoeg te voorspellen. Nachtelijke 
metingen zijn nodig als men precies geïnformeerd wil zijn over de nachtelijke 
zuurstofsaturatie. 
• Meting gedurende één nacht was voldoende om het nachtelijke zuurstofsaturatie-
en het ademhalingspatroon te bepalen van COPD-patiënten. 
• 24 procent van de onderzochte COPD-patiënten met een Pa02 van tenminste acht 
kPa ontwikkelde nachtelijke hypoxaemie (gemiddelde nachtelijke Sa02 < negentig 
procent). 
• Geen van de onderzochte COPD-patiënten met een Pa02 overdag boven de elf 
kPa ontwikkelde nachtelijke hypoxaemie. Meting van de hypercapnische ventilatoire 
respons bleek waardevol te zijn als screeningstest ter voorspelling van nachtelijke 
hypoxaemie bij COPD-patiënten met een РаО
г
 overdag hoger dan acht kPa en 
lager dan elf kPa. Patiënten met een hoge hypercapnische ventilatoire respons 
hebben weinig kans op nachtelijke hypoxaemie. 
• Continue meting van de PETCOJ gedurende de nacht detecteerde apnoes en 
hypoventilatie/hypopnoes bij COPD-patiënten mèt en zónder zuurstofsuppletie en 
bij personen verdacht voor een slaapapnoe/hypopnoe-syndroom. 
• De video-bewegingsdetector bleek een klinisch bruikbare methode ter vaststelling 
van slaaptijden en bewegings-arousals. Het is hiervoor een goed alternatief indien 
conventionele EEG slaapanalyse niet gewenst danwei niet beschikbaar is. 
• De selectieve aandacht van COPD-patiënten was laag t.o.v gezonden uit dezelfde 
leeftijdscategorie. Behalve leeftijd bleek alleen de laagste zuurstofsaturatie 's nachts 
onafhankelijk bij te dragen aan de voorspelling van de selectieve aandacht. 
• Chbrmadinon-acetaat en acetazolamide verlaagden de PC02-waarde overdag en 
's nachts van de groep onderzochte hypoxaemische COPD-patiënten tot een 
vergelijkbaar niveau. 
• Het effect van acetazolamide op de oxygenatie 's nachts en overdag en op de 
subjectieve slaapkwaliteit was beter dan die van chlormadinon-acetaat. 
• Acetazolamide verbeterde de oxygenatie overdag tot hetzelfde niveau als zuurstof-
suppletie. 
• Zuurstofsuppletie deed de PC02 overdag en 's nachts toenemen en had geen 
significant effect op de slaapkwaliteit. 
• Zeventien procent van de hypoxaemische COPD-patiënten behandeld met chlorma-
dinon-acetaat, en 53 procent van de groep behandeld met acetazolamide, bereikte 
hiermee acceptabele P02- en PC02-niveaus. 
• COPD-patiënten die gunstig reageerden op chlormadinon-acetaat of acetazolamide, 
konden niet onderscheiden worden van diegenen die niet gunstig reageerden, als 
gebruik gemaakt werd van de longfunctie, de hypercapnische en hypoxische 
ventilatoire responsen of de bloedgaswaarden overdag. 
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List of abbreviations 
ACET 
AHI 
CMA 
COPD 
EEG 
EMG 
EOG 
f 
FEV, 
FRC 
HCVR 
HVR 
IVC 
NREM 
o2 OSA 
PaC02 
Pa02 
PETC0 2 
% predicted 
REM 
RV 
Sa02 
SD 
TLC 
vE 
т 
WASO 
Acetazolamide 
Apnoea/hypopnoea index 
Chlormadinone acetate 
Chronic obstructive pulmonary disease 
Electroencephalogram 
Electromyogram 
Electrooculogram 
Breathing frequency 
Forced expiratory volume in one second 
Functional residual capacity 
Hypercapnic ventilatory response 
Hypoxic ventilatory response 
Inspiratory vital capacity 
Non-rapid-eye-movement 
Oxygen 
Obstructive sleep apnoea syndrome 
Partial carbon dioxide pressure in the arterial blood 
Partial oxygen pressure in the arterial blood 
Partial carbon dioxide pressure in the end tidal expiratory air 
Per cent of predicted value (1) 
Rapid-eye-movement 
Residual volume 
Oxygen saturation in the arterial blood 
Standard deviation 
Total lung capacity 
Minute ventilation 
Tidal volume 
Wake after sleep onset 
1. Quanjer Ph. Standardized lung function testing. Clin Respir Physbl 1983;19:suppl 
5:1-95. 
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1. Indien men precies gemformeerd wil zijn over het nachtelijke zuurstotsaturatie-
patroon van patiënten met een ernstig chronisch obstructief longlijden, moet men 
daadwerkelijk 's nachts meten 
Dit proefschrift 
2. Normoxie overdag bij COPD-patienten is geen garantie voor normoxie 's nachts 
Dit proefschrift 
3. Hypoxie overdag bij COPD-patienten betekent meestal toename van de hypoxia 
's nachts. 
Dit proefschrift 
4. Het blijkt mogelijk, enkel met ademhalingsstimulantia, normoxie overdag en 's 
nachts te bereiken, bij een gedeelte van de hypoxische COPD-patienten 
Dit proefschrift 
5 Hypercapme bij COPD-patienten neemt toe tijdens zuurstofsuppletie, doch kan 
door ademhalingsstimulantia verminderd worden 
Dit proefschrift 
6. Chronische 18-uurs zuurstofsuppletie wordt nog vaak op verkeerde gronden 
voorgeschreven 
Eigen waarneming 
7. Tot zes weken na een exacerbatie van een chronisch obstructief longlijden 
kunnen de arteriele bloedgaswaarden overdag en 's nachts verbeteren 
Eigen waarneming 
8. Het obstructieve slaapapnoe-syndroom wordt in Nederland ondergediagnosti-
seerd 
9. De meeste patiënten met een ernstig obstructief slaapapnoe-syndroom, zijn meer 
gebaat bij een behandeling met CPAP (continuous positive airway pressure) dan 
bij het ondergaan van een UPPP (uvulo-palato-pharyngoplastiek) 
10. Sommige snurkers brengen adembenemende nachten door 
11. Anno 1992 hebben vrouwen en mannen nog steeds geen gelijke mogelijkheden 
12. Zoals de klokjes bij Hans thuis tikken, tikken ze nergens 



